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                                                  1. INTRODUCTION 
      Analytical method development and validation plays a main role in the discovery, 
development and manufacture of pharmaceuticals. Analytical methods are used to ensure 
identity, purity and potency of the drug products. There are various factors to be 
considered while developing analytical methods. At first collect the information about 
the analyte’s physicochemical properties for e.g. pKa, log p, solubility etc. 
      The analytical chemistry is often be the described the area of chemistry responsible 
for characterizing the composition of the matter, both qualitatively (what is present) and 
quantitatively (how much is present). Analytical chemistry is not separate branch of 
chemistry, but simply application of chemical knowledge. The pharmaceutical analyst’s 
in the respective quality control and quality assurance department (QA&QC) will check 
whether the products are complying with the standard or not. [1-2]                      
 
There are mainly two types of chemical analysis: 
  1. Qualitative (Identification)  
  2. Quantitative (Estimation) 
 
1. Qualitative analysis: It is performed to establish composition of natural or synthetic 
substances. These tests are performed to indicate whether the substance or compound is 
present in the sample or not. 
2. Quantitative analysis: This is mainly used to quantify any compound or substance in 
the sample. 
Common techniques for analysis 
1. Chemical methods [3] 
                   a) Volumetric or titrimetric methods 
                   b) Gravimetric methods 
                   c) Gasometrical analysis 
2. Electrical methods 
3. Instrumental methods 
4. Biological and microbiological methods [4-7]   
       There are various types of instrumental methods available for the analysis of the 
drugs and drug products. Some of them are             
 UV –Visible spectrophotometry 
 Infra-red spectrophotometry (IR) 
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 X-ray spectroscopy 
 Nuclear magnetic spectroscopy (NMR) 
 High performance liquid chromatography (HPLC) 
 High performance thin layer chromatography (HPTLC) 
 Mass spectrometry 
 Gas chromatography-mass spectrometry (GC-MS) 
 Liquid chromatography-mass spectrometry (LC-MS) 
1. Chemical methods: 
a) Titrimetric and volumetric methods: 
       It involves the reaction of separation in substances to be determined with the 
appropriate reagent as the standard solution and volume of solution required to complete 
the reaction is determined. 
b) Gravimetric methods: 
        In gravimetric analysis, a substance to be determined is converted to an insoluble 
precipitate in the purest form, which is then collected and weighed.        
c) Gasometrical analysis: 
       Gasometry involve the measurement of volume of gas evolved or absorbed in a 
chemical reaction.  
2. Electrical methods: 
        Electrical methods of involve the measurement of electric current, voltage or 
resistance in relation to the concentration of some spices in the solution. Electrical 
methods of analysis include 
1. Potentiomety 
2. Conductometry 
3. Polarography 
4. Voltammetry 
5. Amperometry 
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3. Instrumental methods of analysis: 
         Instrumental methods involve the measurement of some physical properties of the 
compounds. 
 
a) Spectrophotometric methods: 
The spectroscopic method of analysis is depends upon the measurements of the 
amount of radient energy of particular wavelength emitted or absorbed by the 
sample. 
b) Chromatographic techniques: 
The chromatographic techniques are separation methods for the mixture of 
compounds and also applied for identification of compound of mixtures. Various 
chromatographic techniques are GC, HPLC, HPTLC, TLC, PC etc. 
c) X-ray methods: 
When high speed electrons collide with a solid target, X-rays are produced. From 
the remittent X-ray emission, it is possible to identify the certain emission peaks, 
which are characteristic of elements contained in target. 
d) Radioactivity: 
It involves measurement of the intensity of the radiation from naturally 
radioactive substances or induced radioactive substance arising from exposure of 
sample to a neutron source. 
e) Optical methods: 
   i)    Refractometer: based on measurement of refractive index of a liquids 
          ii)  Optical rotation: for optically active compounds. 
f) Thermal methods: 
Changes in weight or changes in energy, record as a function of temperature like 
a Thermo gravimetry, Differential scanning calorimetry etc. 
 
4. Biological and micro-biological methods: 
         Biological method is used when potency of a drug or its derivative cannot be 
properly determined any physical or chemical methods. They are called as bio-assays. 
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        Micro-biological method is used to observe potency of anti-biotic or anti-
microbiological agents. These methods include cup plate method and turbidimetric 
analysis. 
 
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY: 
     HPLC is one of the modern chromatographic techniques which are widely used in the 
fields of clinical research, bio-chemical research, industrial quality control etc. 
Application of these methods includes detection, analysis, determination, quantification 
and derivation of molecules from mixtures of biological, plant and medical samples. In 
column chromatography the solvent is just allowed drip through the column in high 
performance liquid chromatography, it is forced externally through the column at very 
high pressure up to 400 atmosphere. This will turn make the process lot faster. It also 
permits the very small particle size for the column packing material which offers a much 
greater surface area for interaction between the stationary phase and molecules flowing 
through it. High performance liquid chromatography be situated only of the best 
powerful tools now the analytical chemistry in means of the capacity to identify, separate 
then quantitate the compound that is existing in sample that is dissolved in every liquid. 
      HPLC method as the several advantages similar to rapidity, specificity, accuracy, 
precision, as well as ease automation now this method. HPLC method eliminates tedious 
extraction and isolation procedures. 
       The advancements in technologies trace concentration of compounds as low as parts 
per trillion can be easily too identified. HPLC can be applied to any sample such as, 
food, pharmaceutical, forensic sample, neutraceuticals, cosmetics, industrial chemical, 
environmental samples. There are two types of HPLC normal phase and reverse phase 
HPLC. 
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1) Normal phase HPLC: 
     The column is filled with tiny silica particles, and the solvent is non-polar-for 
example hexane. A typical column has an internal diameter of around 4.6mm, and 
length in the range of 150-250mm. polar compounds in the mixture which is passed 
through the column will stick longer to the silica longer to the polar silica than to the 
non-polar compounds. Hence the non-polar compounds will elute faster.  
2) Reverse phase HPLC: 
     The column size is the similar as in normal phase HPLC, but silica is modified      
and completed non-polar attaching by long hydrocarbon chains to its surface with 
their 8 or 18 carbon atom in them. A polar solvent is used in this type of HPLC- for 
example, a mixture of an alcohol such as methanol and water is used. There will be a 
strong magnetism between the polar molecules and polar solvent in the mixture 
which is passing through the column. The attraction between the hydrocarbon chains 
attached to the silica (the stationary phase) and the polar molecules in the solution 
won’t be as much. Therefore, polar molecules in the mixture will spend most of their 
time moving with the solvent. Because of van-der Waals forces the Non-polar 
compounds in the mixture will tend to form attractions with the hydrocarbon groups 
present in the stationary phase. RP-HPLC method is the most commonly used for 
analysis. [8-13]   
 
Characteristics features of HPLC: 
        HPLC method is having many advantages than the conventional method of analysis, 
in which the following is included; 
 High resolving power and speed of separation. 
 Accurate and quantitative measurement. 
 Repetitive and reproducible analysis using the same column. 
 Determination of several components in a single analysis. 
 Easy collection of separated components for further characterization. 
 A variety of solvents, column, and detectors are available. 
 Readily automated data handling.    
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PRINCIPLE: 
        The principle of separation is based on the typical modes of separation of that of a 
classical chromatography 
1) Adsorption 
2) Partition  
3) Ion exchange 
4) Gel permeation 
Adsorption chromatography 
      Adsorption is a surface phenomenon where the separations of components are 
achieved by adsorption to the stationary phase. It involves the accumulation of the liquid 
or gaseous solute on to the surface of the solid particle. The separation is based on 
affinity characters of the with stationary phase. Compounds having less affinity with 
stationary phase will eluted faster while those compounds more affinity with stationary 
phase will be eluted later. 
 Partition chromatography 
      In this method the stationary phase will be liquid coated with solid support. Here the 
separation is achieved based on the relative distribution solute between two liquid phases 
i.e; based on the partition co-efficient value. This type chromatography may be either 
normal phase or reverse phase depending on the nature of mobile phase and stationary 
phase. 
 Ion-exchange chromatography 
        This method involves reversible exchange of charged ions between the stationary 
ion exchange resin and liquid mobile phase. Separation is achieved due to the 
difference in strength of electrostatic interaction of solutes with the stationary phase. 
 Gel permeation chromatography 
                 The mechanical sorting of molecules take place based on the size of the  
molecules in solution. Small molecules are able to permeate through the pores and 
therefore longer than larger molecules and hence molecules are elute first. [14-16]   
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  Table 1: Various Types of HPLC 
TYPE SAMPLE 
POLARIZA
TION 
MOLECULAR 
MASS 
RANGE 
STATIONARY 
PHASE 
MOBILE 
PHASE 
Adsorption non-polar to 
somewhat 
polar 
100– 104 silica or alumina non-polar to 
polar 
Partition 
(reversed-
phase) 
non-polar to 
slightly polar 
100– 104 non-polar liquid 
adsorbed or 
chemically bonded to 
the packing material 
relatively 
polar 
Partition 
(normal-
phase) 
To some 
polar to 
greatly polar 
100– 104 highly polar liquid 
adsorbed or 
chemically bonded 
toward the packing 
material 
relatively 
non-polar 
Ion 
Exchange 
extremely 
polar to ionic 
100 – 104 ion-exchange resins 
complete of 
insoluble, high-
molecular mass solids 
functionalized 
characteristically 
through sulfonic acid 
or amine groups 
aqueous 
buffers by 
added 
organic 
solvents to 
moderate 
solvent 
strength 
Size-
Exclusion 
non-polar to 
ionic 
103 – 106 small, porous, silica 
or polymeric particles 
polar to 
non-polar 
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Quantitation methods in HPLC: 
        The peak height and peak area measured by the detector signals. This measurement 
will give an account about the concentration or mass of the compound. For establishing 
this quantitation, some sort of calibration should be performed. 
                The major techniques for quantitation are: 
1. Normalized peak area method 
2. External standard method 
3. Internal standard method 
4. Method of standard addition method 
Normalized peak area method 
      To determine the degradation product or impurity in a product, this method is used. 
The peak area of any one of the peak is referred to the normalized peak area. The 
response factor for each component is identified by this method. 
External standard method 
       This method is done by injecting both standard and unknown sample. The unknown 
can be determined by calculating the response factor or calibration graph. The response 
factor Rf can be calculated from the following formula 
                        Rf =   
௦௧௔௡ௗ௔௥ௗ ௣௘௔௞ ௔௥௘௔
௦௧௔௡ௗ௔௥ௗ ௖௢௡௖௘௡௧௥௔௧௜௢௡
 
      
         There is no need of extensive sample preparation. The chromatographic conditions 
should be maintained constant during the separation of all standards and samples for 
better quantitation using external standard method. External standard methods are mainly 
used to ensure that the total chromatographic system is properly and can provide reliable 
results. 
Internal standard method 
         A compound which is different from the analyte is used as the internal standard. 
But that compound should be resolved in the separation. The purpose of internal standard 
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is to mimic the nature and behavior of sample. For compounds which need pre-treatment 
or preparation this internal standard method is used. 
        The response factor is used for the determination of sample component in the 
original sample. Response factor is defined as the ratio of peak area of sample 
component (Ax) and the internal standard (AISTD). The formula is follow as, 
                                  Rf=  
 
          Based on the response factor and strength of  internal standard (NISTD ), the amount   
of analyte in the original sample can be calculated from the formula, 
                              X =    
 
Method of standard addition 
          The method of standard addition can be used to provide calibration plot for the 
quantitative analysis. An important aspect of this method is that the response prior to 
spiking additional analytes should be high enough to provide to provide a reasonable S/N 
ratio (>10), otherwise the result will have poor precision. Mostly this method is used in 
the trace analysis. [17-18]   
 
 
 
 
 
 
 
 
 
 
std
x
AI
A
STD
ISTDF
x N
AR
A 

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Instrumentation of HPLC: 
      The features of modern HPLC is illustrated in the block diagram comprise of 
components.
 
                                              Fig.1: schematic diagram of HPLC 
 
1.       Pumping system: 
          HPLC pumping technique is required toward deliver metered amounts of mobile 
phase on a constant flow rate. Pumping system that is delivers solvent from one or more 
reservoirs be there available. Modern computer- or micro processer- controlled pumping 
systems are capable of delivering a mobile phase of either constant (isocratic elution) or 
either (gradient elution) composition, according to a defined programme. 
Features of pumping systems: 
       High pressures up to 6000 psi, constant & reproducible flow, pulse free output, flow 
rate (0.1-10ml), adaptable to gradient flow, corrosion to resistant components. Easy to 
dismantle & repair and low maintenance cost. 
2. An injector: 
           The sample solution is commonly introduced now toward the flowing mobile 
phase at or nearby the head of the column usage through means of an injection system 
based on injection value design which can operate at high pressure. Such as an injection 
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system has a fixed loop or a variable column devise which can operated manually or by 
an auto sampler. Partially filling of tuber may lead to poorer injection volume precision. 
3. Chromatographic column: 
          A tube which contains the stationary phase. The stationary phase differentially 
interrelates through the sample constituent compounds they are carried along with the 
mobile phase HPLC column is packed with very fine particles (usually few microns in 
diameter). 
Types of column: 
 Analytical column: 
It performs the separation. It is a straight column with dimensions 4.0-8.0 mm 
(id) X 15cm or 25 cm length and particle size of 5or 10 micron. It contains 
40000-60000 plates/m. 
 Preparative column: 
It is 25-50mm (id) X 25cm (length) and used for preparative works. Its important 
parameters are sample load and transfer of analytical data to preparative data. 
4. Detector: 
         The detector controls the sensitivity with which each compound can be detected 
and measured, once separated on the column. It must be capable of responding to 
concentration in all of the compounds of interest. 
       There are six main detectors used for HPLC. Refractive index (RI), ultraviolet (UV), 
fluorescence (FD), conductivity (CD), electrochemical (EC), and mass spectrometric 
(MS). 
         Ultraviolet visible (UV/Vis) absorption spectrometer is the most commonly used 
detectors for pharmaceutical analysis. [19-20] 
  Data system: 
 For better accuracy and precision. 
 Routine analysis: pre-programmed computing integrator. 
 Data station/ computer needed for higher control levels. 
 It adds automation options and complex data becomes more feasible. 
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  System suitability parameters: 
        System suitability parameters toward ensue recognized intended for a specific 
process depend on the type of process which being validated. The simplest form of a 
system suitability test involves a comparison of the chromatogram trace with a standard 
trace. This allows the comparison of the peak shape, peak width, and base line 
resolution. These are few parameters that can be calculated to provide a quantitative 
system suitability test report. 
 Number of theoretical plates (efficiency) 
 HETP 
 Capacity factor 
 Peak asymmetry factor 
 Resolution  
 Tailing factor 
i) Resolution (Rs): 
        The resolution Rs, two neighboring peaks is defined as the ratio of the distance 
between the two peaks maxims. This one of the located the variance among the retention 
times of double solutes divided in their average peak width. Intended for baseline 
separation, the ideal value of Rs is 1.5. It is calculated by using the formula,    
                                              Rs   =  21
12
5.0 WW
RtRt


 
               Where, Rt1 and Rt2 are the retention time of component 1 and 2 and  
                W₁ and W₁ are peak widths of component 1 and 2. 
ii) Capacity factor (K): 
          Capacity factor, K, is defined as the ratio of the number of molecules of solute in 
the stationary phase to the number of molecules of the same in the mobile phase. 
Capacity factors are measure of exactly how well the sample molecule is retained in a 
column or TLC plate during an isocratic separation. The ideal value of K ranges from 2-
10 capacity factors can be determined by using the formula, 
                           K   = S
V
VV 
0
01  
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         Where, V1 = retention volume on the top of the peak (solute) 
                      V₁= void volume of the system 
               The values of K of individual band increase or decrease with changes in solvent 
strength. In reversed phase HPLC, solvent strength increases with the increase in the 
volume of organic phase in the water / organic mobile phase. Typically an increase in 
percentage of the organic phase by 10% by volume will decrease K bands by a factor of 
2-3. 
iii) Column efficiency (N): 
          Efficiency, N, of a column is measured by the number of theoretical plates per 
meter. It is a measure of band spreading of single peak. Smaller the band width, higher is 
the number of theoretical plates, indicating good column and system performance. 
Columns through N ranging from 2000 – 100,000 plates/meter are suitable intended for 
good system. Efficiency is calculated by means of using the formula, 
                                     N   =   2
2
16
W
Rt
 
                       Where, Rt is the retention time and W is the peak width. 
iv) Peak asymmetry factor (As): 
         Peak asymmetry factor, As, can be used as a criterion for checking column 
performance. The peak half width, b, of a peak at 10% of the peak height, divided by the 
corresponding front half width, a, gives a asymmetry factor. 
                                              As =
a
b  
          For a well packed column, an asymmetry factor of 0.9 to 1.1 should be achievable. 
[21-25] 
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 Table 2: System suitability parameters and recommendations 
Parameter Formula Recommendation 
 
Theoretical Plates 
(N) 
 
N=5.54*(tR/W0.5)2 
 
In general should be > 2000 
 
HETP(H) 
 
H= L/N 
 
HETP↓ Column efficiency↑ 
 
Peak asymmetry (As) 
 
As= b/a 
 
In general it should be 1 
 
Tailing Factor (T) 
 
T= (b+a)/2a 
 
In general it should be 1 
 
Resolution  (R) 
 
21
122
WW
tt
Rs 
  
 
Rs of > 2 between the peaks of 
interest. 
  
    HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY: 
            Thin layer chromatography (TLC) is also well-known as planar chromatography 
or flat chromatography similar all other chromatographic techniques, a multi stage 
distribution process. The most advanced form of TLC is commonly called high 
performance thin layer chromatography (HPTLC). 
            In most of the pharmacopoeial monographs thin layer chromatographic studies 
are the key identifying tests. The pharmacopoeial standard values are being used by 
industries as a basis for a quality control and current good manufacturing practices 
(CGMPs). In advancement of TLC be there high performance thin layer chromatography 
(HPTLC) remains robust, simple, rapid then an efficient tool in quantitative or 
qualitative analysis of compounds. HPTLC has an increased resolution than TLC which 
allows the clear and quantitative separation of the compounds. One of the enhancements 
is the use of higher quality TLC plates with finer particle sizes in the stationary phases. 
The separation can be further more improved by repeated development of a plate, using a 
multiple development device. As result, HPTLC offers better resolution and lower limit 
of detection (LODs). 
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            HPTLC is the highest flexible, reliable then cost-efficient separation technique 
preferably suited for the analysis of botanical and herbal drugs etc. used through 
standardized then validated processes, it guarantees reproducible results. HPTLC is a 
vital element routine identification of complex finger prints of plant extracts and 
pharmaceutical products. It has established itself as the method of choice for handling 
complex analytical task involving identification of herbal drugs and botanicals. 
            High throughput analysis using HPTLC helps in the rapid analysis of large 
number of compounds. This field has been expedited by the requirements to provide 
analytical support of multiple drug targets emerging from the field of molecular biology, 
human genetics and functional genomics. 
          The power of thin layer chromatography has been improved by considering the 
chromatographic principles to enhance the speed and efficiency of separation by 
development of instruments to automate sample application, development of 
chromatogram and detection including accurate and precise quantification and 
identification. As the particle size of layer is decreases, the separation will be faster, 
more resolved and efficient. The particle size of the stationary phase has a narrower 
distribution range with an average size of 5µm, instead of average of 20µm for 
conventional TLC. The use of mechanical applicators like linomat 5, produce 
reproducible application reduces the diameter of the starting spots, compared to 
conventional TLC, only few volumes of sample are used in HPTLC, i.e; about one-tenth 
of the sample. The separation time is also reduced considerably. 
        Modern thin layer chromatography can be complementary to the HPLC technique. 
It allows the analysis of many samples in parallel, providing low cost analysis of simple 
mixtures for which the sample workload in high. The TLC plates acts as a “storage 
detectors” of the analytes if they are saved properly. [26-28] 
 
     Factors influencing the TLC / HPTLC separation and resolution of 
spots: 
 Type of stationary phase 
 Layer of thickness / binder in the layer 
 Mobile phase (solvent system) 
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 Size and saturation of the developing chamber 
 Sample volume to be spotted  
 Solvent level in the chamber 
 Relative humidity 
 Temperature (Rf values with increase with rise in temperature) 
 Separation distance 
Features of HPTLC: 
1. Simultaneous processing of sample and standard, it shows better analytical 
precision and accuracy, less need for internal standard, 
2. Several analysts work simultaneously, 
3. Lower analysis time and less cost per analysis, 
4. Low maintenance cost, 
5.  Simple 
6.  Low mobile phase consumption per sample, [29-31] 
HPTLC METHODOLOGY: 
      Set the analytical objective main that can exist quantification or qualitative 
identification or separation of twofold components/multicomponent combinations or 
optimization of analysis while before starting HPTLC. Process demands primary 
knowledge about the nature of the sample, namely, structure, polarity, volatility, stability 
and the solubility parameter of the sample. 
      Method improvement includes considerable test and error procedures. Selection of 
stationary phase exists quite easy. That remains to start with silica gel which is 
reasonable and nearly suits all kind of drugs. 
     Mobile phase optimization is done by using three level techniques. 
i) First level involves use of neat solvents by considering the solubility of drugs and then 
by finding some such solvents can have average separation power for the desired drugs. 
ii) Second level involves decreasing or increasing solvents strong point using hexane or 
water intended for respective purposes. This has change in their polarity. 
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iii) Third level involves annoying of mixtures instead of neat particular solvents since the 
selected solvents first and second level which can further be optimized through the use of 
modifiers like acids or bases are desired volumes.  
       Analytes are detected using either fluorescence or absorbance mode. Optimization 
can be started only afterward a reasonable chromatogram which can be finished by slight 
change in mobile phase composition.  
 
  
                                      Fig. 2: steps involved in HPTLC 
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1. Sample preparation: 
Normal phase chromatography: non polar solvents 
Reverse phase chromatography: polar solve 
 
 
2. Selection of chromatographic layer: 
      Precoated plates of different support material (different solvents) are available for 
80% of analysis. Generally plates of 20 × 20cm or 10 × 10cm size having 100-250mm 
adsorbent thickness are used. 
 Alkaloids and steroids – aluminium oxide, silica gel 60 GF₁₁₁ 
 Amino acids, dipeptides, sugars and alkaloids – cellulose 
 Non-polar substances, fatty acids, carotenoids and cholesterol – RP-2 and 
RP-8 
 Preservatives, barbiturates, analgesics, phenothiazine – hybrid plates (RP-
WF₁₁₁) 
 
3. Layer pre washing: 
        It is a purification step to remove water vapours present in the plate. This step also 
removes the volatile impurities which might get trapped in the plates. Mainly methanol is 
as a solvent for washing by ascending or descending technique. This step is very 
essential for quantitative evaluation and stability testing of drugs. 
4. Conditioning of pre coated plates: 
         Freshly open box of plates do not require activation. Plates exposed to high 
humidity or kept on hand for long time is to be activated. Activation is done by using the 
plate in oven at 110 to 120ºc for 30minutes prior to spotting. Dried plates are stored at 
dust free atmosphere. 
5. Sample application: 
       The samples are applied on to the separation layer, either as spots through capillary 
tube or as narrow bands using the spray-on technique by the help of a sample applicator. 
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The criteria like precision of applied volume, small size of application zone and exact 
positioning of sample are essential for the quality or repeatability of the analysis. Usually 
the concentration range between 0.1-1µg/µl. Above this causes poor separation. Band 
wise sample request open through linomat 5 applicator or automatic TLC sampler 4 
which operates the best separation regarding sample and application volumes. Nitrogen 
gas, spray the sample and standard from syringe on TLC plates as bands. Band wise 
application provides better separation which gives high response to densitometer giving 
good results. By using spray-on technique the applied volume can be easily adjusted to 
match the required detection limit of the analytical task. 
6. Selection of mobile phase: 
      Trial and error or one’s own experience and literature helps in the selection of mobile 
phase 3-4 component mobile phase should be avoided. Multi component mobile phase 
while used not mentioned for extra use and solvent composition exists expressed by 
volume (v/v) and sum of volumes is usually 100 twin through chambers are used which 
requires only 10-15ml of mobile phase. Components of mobile phase must be mixed and 
introduced now to the twin through chamber. 
7. Pre- conditioning (chamber saturation): 
     Un-saturated chamber causes high RF values and improper solvent front. Saturated 
chamber through inside layer by filter paper for 30 minutes later to development uniform 
distribution of solvent vapours-less solvent meant for the sample to travel lower RF 
values. 
8. Chromatogram development: 
     Chromatogram is developed by capillary force. The developing solvent (mobile 
phase) migrates through the layer (stationary phase) over a defined distance called 
solvent front. During this process the sample is separated into fractions/bands 
(components). After evaporation of the mobile phase by keeping the layer/plate in hot air 
oven or at room temperature, all fractions remain stored on the layer. 
9. Derivatization: 
      It is a special advantage of planar chromatography that fractions are stored on the 
plate and can be derivatized after chromatography. By Derivatization, substances do not 
respond to visible or UV light can be rendered detectable. In case of certain compounds, 
substances or classes of substances can be identified by using specific reagents.  
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Eg: Ninhydrin, Dragandroff’s reagent  
10. Chromatogram evaluation: 
     The chromatogram is evaluated under UV light or white light detection under UV is 
first choice nondestructive. The various methods involve visual inspection, electronic 
image processing, video densitometry and documentation to quantitative determination 
by means of monochromatic light in a classical densitometer. This additionally facilitates 
measurement of spectral information. Two types of ultra violet light are required by 
inspecting thin layer chromatogram. 
 Long wave UV light 366nm: 
           Some substances may naturally inherent or reagent may induce fluorescence 
which appears at bright spots, often differently coloured, on a back ground. The 
sensitivity of this detection method is proportional with the intensity of the long-wave 
UV light and also as more visible light is eliminated. A fluorescent compound F254 
contained in the layer does not interfere with this detection method. 
 Short wave UV light 254nm: 
          Substance absorbing at this wavelength become visible provided that TLC layer 
contains a fluorescent indicator F254. This substance appear as dark spots on a back 
ground UV intensity and complete elimination visible light are less critical for this 
detection method. 
     Spots of non-fluorescent compound ethambutol, dicylomine etc are dipping the plates 
in 0.1% iodine solution.    
11. Scanning and documentation: 
       A standard flatbed scanner is a viable tool for quantitative thin layer 
chromatographic (TLC) plate analysis. The imaging scanner uses a gas filled 
proportional counter, which can entire TLC lane in less than one minute. The system 
includes winCATS software for instrumental control, data analysis, and report 
generation. The scanner converts bands into peaks. Peak height and area are related to 
the concentration of substance in the spot. Quantification of peak is automatically 
performed, and a report showing the method used, chromatogram, and percent of total 
activity for each peak is provided. [32-37] 
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Parameters that are affected by the changes in chromatographic 
conditions are: 
 Retention factor (Rf ) 
 Peak purity 
 
 
 
1. Retention factor (Rf ): 
        Retention factor is defined such as the quantity of separation due to the solvent 
migration through the sorbent layer as shown in the formula. It depends on time of 
development and velocity coefficient or solvent front velocity. 
                                               
                                                  Migration distance of substance from origin 
Rf =      ---------------------------------------------------------------- 
              Migration distance of solvent front from origin 
  2. Peak purity:  
        The null hypothesis “these spectra are identical” can in this case (purity) with two 
sided significance. Through the purity test the spectrum in use at the first peak slope is 
correlated by the spectrum of peak maximum [r (s, m)] then the correlation of spectra 
taken at the peak maximum by the one from the down slope or peak end [r (m, e)] which 
is used by way of a reference spectra for statistical calculation. An error probability of 
1% only is rejected if the test value is greater than or equal to 2.57. [38] 
 
Quantitative analysis:                                                
        The primary goal of the method is to provide validated methods to be used for the 
quantification of the compounds most correlated with pharmacological activity or 
qualitative markers as determined by the primary pharmacological literature, product 
labeling and survey of experts. The method will be selected from the primary analytical 
literature by a methods selection committee with priority given to compendia methods 
when available. In this context, validation consists minimally of a two lab validation 
using the same procedures, samples and reference standards. Primary factors for 
considering methods as appropriate include accuracy of the findings, speed, basic 
ruggedness, applicability to a large segment of the manufacturing community, and 
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avoidance of the use of toxic reagents and solvents. In an attempt to promote 
harmonization, primary consideration is given to those methods which are already 
accepted in official pharmacopeias. When necessary, comparative tests shall be 
conducted to determine which of the available method is most appropriate. [39] 
 
VALIDATION OF ANALYTICAL PROCEDURE: 
  Significance of method validation: 
         The quality of analytical data is a key factor in the success of a drug development 
programmer. The process of method development then validation takes a complete 
impact on the quality of these data. 
 To trust the method 
 Regulatory requirement 
 
Different types of validation characteristics: 
 Precision 
 Repeatability 
 Inter and intraday precision 
 Accuracy  
 Specificity/selectivity 
 Linearity range 
 Limit of detection (LOD) 
 Limit of quantification (LOQ) 
 Robustness  
 Ruggedness  
 System suitability 
Generalized validation process for HPLC assay methods 
 Validation is the process of collecting documented evidence that the method 
performs according to its intended purpose. The validation process as follows:  
 
 
1. Precision: 
        The closeness of contract between a sequence of measurements of multiple 
samplings of the same homogeneous sample under prescribed condition. The precision 
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of a test method is usually expressed as the deviation or relative deviation of a series of 
measurements. 
 Precision may be considered at three levels:  
 Repeatability  
 Interday and  
 Intraday Precision. 
 
Acceptance Criteria: 
 Percentage Relative  deviation (%RSD)  NMT 1 % (Instrument precision) 
 (%RSD)  NMT -2% (Intra- assay precision) 
 
2. Accuracy: 
  The ICH guideline mentions that accuracy requirement be determined by a smallest 
of nine determinations over a minimum of three concentration levels covering the 
identified range. The spiked samples are prepared now triplicate at three levels over a 
range that covers 80 -120% of the target concentration for assay methods .There are 
several methods that can be used for determining accuracy.           
In this case, method accuracy is the agreement between the differences in the 
measured analyte concentration and the known amount of analyte added. That is the 
accuracy or % recovered is calculated as:  
Accuracy =            Cm ×     100 
       Ct 
   Where; Cm is the measured concentration  
                Ct is the theoretical concentration.            
        Accuracy has also been reported as; when a sample is analyzed the measured value 
should ideally be identical to the true value. Accuracy is represented and determined by 
the recovery experiments. The usual range is being 10% above or below the expected 
range of claim. The % recovery was calculated using the formula, 
100
)(covRe%
bX
abaery   
 
Where, 
 a – Amount of drug present in sample 
 b – Amount of drug added to the sample 
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Acceptance Criteria: 
 For an assay method, mean recovery will be 100%± 2% at each concentration 
over the range of 80-120% of the target concentration. 
 
 
 
3. Limit of Detection: 
 The condition is previous amount of analyte now a sample analyzed that contain exist 
detected but not necessarily be quantitated below the stated experimental conditions. 
  
Following are different approaches: 
 
i. Based on Signal to Noise Ratio Method: 
       The LOD can be expressed as a concentration at specified signal-to-noise ratio 
obtained from samples spiked with analyte. A signal-to-noise ratio is 3:1 is generally 
considered to be acceptable. 
 
ii. Based on the Deviation of the Response of the Slope: 
 Prepare the blank solution as per test method inject six times into the 
chromatographic system. 
 Similarly prepare the linearity solution starting from lowest possible 
concentration of analyte to 150% of target concentration and establish the 
linearity curve. 
 The detection limit (DL) may be expressed as: 
LOD = 3.3 σ / S 
      The slope shall be estimated from the calibration curve of the analyte. 
 
 
4. Limit of quantification: 
 It is lowest amount of analyte in a sample, which can be quantitatively determined is 
LOQ. 
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LOQ = 10 σ / S 
 
 
 
Acceptance Criteria: 
 In Pharmaceutical application, the LOQ is typically set at minimum 0.05% for 
active pharmaceutical ingredients.      
 
 
 
5. Linearity range:  
 The linearity of an analytical method is its ability to evoke test results that are 
consider to the analyte concentration in samples within a given range. The working 
sample concentration tested for accuracy should be in the linear range. The demand that 
the method is linear is to be justified with additional mention of zero intercept by 
processing data by linear least square regression (R2).  
y = mx +C 
 For the method to be linear the R2 value should be near to1. Where y is the measured 
output signal, x is the concentration of sample, m is the slope, C is the intercept. 
            The range of an analytical method is the interval between the upper and  lower 
levels of the analyte (including these levels) that have been demonstrated to be 
determined with precision, accuracy  linearity using the method as written.  
 
Acceptance criteria: 
 Coefficient of correlation should be NLT 0.99. 
 
6. Robustness: 
  That one is a measure of the method’s capability to remains unaffected done slight 
then deliberate deviations now the parameters, which provides an indication of his 
reliability throughout normal usage.  
                 For example in a chromatographic method, the typical method parameters need to 
change deliberately verify during method validation:  
 Flow rate   : (+/- 0.2ml/minutes). 
  Mobile phase composition : (+/- 10% of organic phase). 
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  PH of buffer in mobile phase : (+/- 0.2 units). 
 
 
 
 
For Variations:  
 1.  System suitability should meet the acceptance criteria as per test method.  
 2.   If system suitability doesn’t meet, narrow the variation range carryout the 
experiment again to meet system suitability. 
  
 
7.  Ruggedness:   
 Ruggedness is near a measure of reproducibility of the test effects under normal 
operational conditions though laboratory to laboratory and after analyst to analyst.  
 The following are the typical method parameters needed to be tested during the 
method validation:  
  Analyst-to-Analyst variability. 
 Column-to-Column variability 
 Different days [40-57] 
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Table 3: Method Validation Requirements (ICH) 
 
METHOD   VALIDATION 
REQUIREMENTS 
ACCEPTANCE CRITERIA 
 
Precision 
Assay repeatability 
Intermediate precision 
(Ruggedness) 
 
≤ 1% RSD 
≤ 2% RSD 
 
Accuracy 
Mean recovery per concentration 
 
100.0% ± 2.0% 
 
Limit of detection 
Signal to-to-noise ratio 
 
≥ 3:1 
 
Limit of quantification 
Signal to-to-noise ratio 
 
≥ 10:1 
 
Linearity/Range 
Correlation coefficient 
y-Intercept 
Visual 
 
>0.99 
                      ± 10% 
  Linear 
               Robustness 
System suitability met 
Solution stability 
 
                                      yes 
± 2% change from time zero 
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                                             2. REVIEW OF LITERATURE 
Ganesh Kumar[58] et al. Developed and validated simple and new stability indicating 
RP-HPLC method for the identification of teneligliptin and its degradants on kromasil 
100-5C18 (250×4.6mm, 5µm) column using pH 6.0 phosphate buffer and acetonitrile 
(60:40 v/v) as  mobile phase in isocratic mode of elution of flow rate of 1.0ml/min. The 
column effluents were monitored by a variable wavelength UV detector at 246nm. The 
method was validated as per ICH guidelines. Forced degradation studies of teneligliptin 
were carried out under acidic, basic, neutral (peroxide), photo and thermal conditions for 
48hrs at room temperature respectively. 
Kadam V.N. [59] et al. Proposed simple accurate, precise and reproducible RP-HPLC 
method was developed for the determination of Voglibose (VGB), Glimepiride (GLM) 
and Metformin HCL (MET). RP-HPLC method was developed on jasco 2075 HPLC 
systems with fine pack ODS C18 column (250mm) and using a mobile phase mixture 
containing mixed acetonitrile: phosphate buffer  in the ratio of 85:15 (pH 4). The flow 
rate was 1ml/min and effluent was monitored at 223nm. The retention time of voglibose, 
glimepiride and metformin HCL were 2.3, 3.8 and 5.1 min respectively. The method was 
validated in terms of linearity, precision, accuracy, specificity and system suitability 
parameters. The proposed method results were found to be satisfactory and are suitable 
for simultaneous estimation of voglibose, metformin and glimepiride for routine quality 
control drugs.  
Sunil R. Dhaneswar [60] et al. validated simple, precise and accurate HPTLC method for 
simultaneous estimation of metformin hydrochloride (MET), atorvastatin (ATV) and 
glimepiride (GLM) as the bulk drug and in tablet dosage forms. Chromatographic 
separation of the drug was performed on aluminium plates precoated with silica gel 
60F₂₂₂ as the stationary phase and the solvent system consisted of water: methanol: 
ammonium sulphate (1: 1: 4 v/v/v). Densitometric evaluation of the separated zones was 
performed at 237nm. The three drugs were satisfactorily resolved with Rf value as the 
0.37±0.02 and 0.59±0.02, 0.75±0.02 for MET, AVT, GLM respectively.  
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Gopal S. Irache [61] et al. developed and validate a simple, rapid and reproducible 
gradient high performance reverse phase liquid chromatographic method for the 
estimation of teneligliptin and metformin in bulk drug sample and pharmaceutical dosage 
forms using cromosil (C18, 250×4.6mm, 5µm) column with mobile phase composition 
of methanol and water (pH 3.5) 50:50 v/v. Flow rate of 0.7ml/min and UV detection at 
242nm was maintain during the entire study. The retention time of metformin and 
teneligliptin was found to be 2.45 min and 6.21 min respectively. Linearity was observed 
over concentration range of 2-10µg/ml and 50-250µg/nl for teneligliptin and metformin 
respectively. The accuracy of the proposed method was determined by recovery studies 
and found to be 98-101%. The proposed method was validated and results conformed to 
ICH parameters. 
Abdul Bari Mohd [62] et al. A simple, rapid sensitive method was carried out on a 5µm 
particle octadesyl silane (ODS) column (250×4.0 mm) with acetonitrile 0.2M phosphate 
buffer (pH 7.4) 40;60 v/v as a mobile phase at a flow rate 1ml/min and quantification 
was achieved at 228nm using PDA detector. The correlation coefficient (r²) was found to 
be 0.999 over the concentration range of 0.2 to 2 µg/ml for glimepiride. The method was 
validated for linearity, accuracy and precision. The limit of detection and limit of 
quantification were found to be 0.38 and 1.17 µg/ml respectively. 
Vishnu C. Shinde [63] et al. developed and validate simple, rapid sensitive and specific 
UV spectrophotometric and high-performance thin layer chromatographic (HPTLC) 
methods for the determination of Teneligliptin Hydrobromide both in bulk drug and 
pharmaceutical dosage form were developed and validated. In UV spectrophotometric 
method, the solutions of Teneligliptin HBr were prepared in water. The standard solution 
of Teneligliptin HBr showed maximum absorption at wavelength 243.5 nm. The drug 
obeyed Beer-lamberts law in the concentration range of 10-90 µg/ml with coefficient of 
correlation (r²) of 0.999. For HPTLC method, the method employed aluminium plates 
precoated with silica gel G60 F₂₂₂ as the stationary phase. The solvent system 
consisted of toluene: chloroform: ethanol: diethyl amine in the proportion of 4: 4: 1: 1 
v/v/v/v. This solvent system was found to give compact spots for Teneligliptin HBr with 
Rf value 0.16±0.01. Densitometric analysis of Teneligliptin HBr was carried out in the 
absorbance mode at 254nm. Linear regression analysis showed good linearity (r²=0.998) 
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with respect to peak area in the concentration range of 100-600 ng/spot. The developed 
methods were validated as per ICH guidelines. 
Deepak Patil [64] et al. accurate, precise and reproducible high performance liquid 
chromatographic method was developed for quantitative estimation of metformin and 
teneligliptin simultaneously in tablet dosage forms. Younglin (S.K.) gradient system UV 
detector and C₂ (Agilent) column with 250mm×4.6mm i.d. and 5µm particle size. 
Methanol: water 0.05% OPA (50:50) was used as the mobile phase for the method. The 
detection wavelength was 235nm and flow rate was 0.7ml/min. In the developed method, 
the retention time of metformin and teneligliptin was found to be 2.1 min and 7.6min. 
The developed method was validated according to ICH guidelines. The linearity, 
precision, range, robustness was within the limits as specified by the ICH guidelines. The 
proposed method can be used for the routine quality control analysis of metformin and 
teneligliptin respectively. 
Pradnya N. [65] et al. a simple reverse phase high performance liquid chromatography 
method was developed and validated for simultaneous determination of metformin 
hydrochloride (MET) and glimepiride (GLM) in combination and estimation of their 
principal degradation products. The separation was achieved using JASCO finepak SIL 
(250mm×4.6mm i.d. 5µm) at ambient temperature. The optimized mobile phase 
composed of an aqueous phase (20 mM phosphate buffer, adjusted to pH 3.0) and an 
organic phase (methanol: acetonitrile, 62.5: 37.5) in the ratio of 80:20. The flow rate was 
1ml/min, and the analytes were detected at 230nm. The developed method was validated 
for accuracy, precision, specificity, linearity and sensitivity. The chromatographic 
analysis time was accurately six minutes with the complete resolution of MET 
(Rt₂2.75minutes) and GLI (Rt₂5.87minutes). The method exhibited good linearity over 
the range of 5-30 µg/ml for MET and 1-10 µg/ml for GLI. The drugs in combination 
were subjected to various stress degradation studies as per the ICH guidelines. 
 
Mastanamma Shaik. [66] et al. developed and validate simple, sensitive, linear, precise 
and accurate method by reverse phase  high performance liquid chromatography for the 
simultaneous estimation of metformin (MET), losartan(LOS) and glimepiride (GLM) in 
bulk and their combined tablet dosage form. The separation of these drugs was based on 
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the use of luna C18 (250×4.6mm, i.e. 5µm) column in a gradient mode. Mobile phase 
consisted of methanol (solvent A) and 0.1% orthophosphoric acid (OPA, solvent B) was 
set with gradient programming for 18min and was delivered at 1ml/min flow rate and 
effluents are achieved with variable wavelength photodiode array detector at 284nm. The 
retention time of MET, LOS and GLI were found to be 3.11, 7.12 and 13.52mins 
respectively. The percentage assay of MET, LOS and GLI was found to be 100.5%, 
100.5% and 100.4% respectively. Calibration curve were linear for MET, LOS and GLI 
at concentration ranges of 30-450 ng/ml and 15-225 ng/ml and 1-18 ng/ml with the 
regression co-efficient of 0.999 for all three drugs and precise with (%RSD>2). The drug 
was subjected to various stress condition of acid and base hydrolysis, oxidation, 
photolysis, thermal degradation and condition. 
Vedantika Das [67] et al. developed and validate simple, accurate, precise and 
economical HPLC method has been developed and validated for the estimation of 
teneligliptin hydrobromide hydrate (THH) in bulk and tablet dosage form. Separation 
was achieved on a prontosil C8 column using a mobile phase consisting of acetonitrile: 
dihydrogen potassium phosphate buffer in 60: 40 (v/v) adjusted with o-phosphoric acid 
pH 3.0. Gradient elution at a flow rate of 1ml/min and UV detection at 246nm. Linearity 
was observed in the concentration range of 30-150 µg/ml. The retention time of 
teneligliptin was 2.47min. The proposed methods were validated according to the ICH 
guidelines.   
M. Vijaya Kumari [68] et al. developed and validate simple, rapid, precise and accurate 
gradient reverse phase HPLC method was developed and validated for the determination 
of teneligliptin in commercial tablets. Separation was achieved on a C8, 150×4.6mm i.d., 
5µm stainless steel analytical column i.e. using a mobile phase a consisting of 1ml OPA 
in 1000ml water and acetonitrile: methanol (80:20) v/v as mobile phase B with pH 5.3 at 
a flow rate of 1ml/min and UV detection at 213nm. The retention time was found to be 
9.8min. The linearity of the proposed method was investigated in the range of 48.6-
148.9µg/ml (r²=0.999). The percent amount of drug estimated by all developed methods 
was nearly 100%, found to be in good agreement with label claim of marketed tablet 
formulation. The recovery study was carried out at three different levels and results were 
found to be satisfactory. The validation parameters like accuracy, precision, ruggedness, 
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linearity and range were studied for all developed methods and were found to be within 
limits.   
Karthik A. [69] et al. developed and validate simple, fast and precise reverse phase, 
isocratic HPLC method was developed for the separation and quantification of 
pioglitazone and glimepiride in bulk drug and pharmaceutical dosage form. The 
quantification was carried out using inertsil ODS (250×4.6mm, 5µm) column and mobile 
phase comprised of acetonitrile and ammonium acetate (pH 4.5; 20mM) in proportion of 
60:40 (v/v). The flow rate was 1.0 ml/min and the effluent was monitored at 230nm. The 
retention of pioglitazone and glimepiride were 7.0±0.1 and 10.2±0.1 min respectively. 
The method was validated in terms of linearity, precision, accuracy and specificity, limit 
of detection and limit of quantification. Linearity of pioglitazone and glimepiride were in 
the range of 2.0 to 200.0µ/ml and 0.5-50µg/ml respectively. The percentage recovery of 
both the drugs was 99.85% and 102.06% for pioglitazone and glimepiride respectively. 
Sharma [70] et al. developed and validate simple reverse phase liquid chromatographic 
method has been developed and subsequently validated for simultaneous determination 
of pioglitazone and glimepiride in combination. The separation was carried out using a 
mobile phase of phosphate buffer (pH 4.5): acetonitrile (45:55 v/v) and using methanol 
as diluent. The column used was inertsil ODS (250×4.6mm i.d., 5µm) with flow rate of 
1.0ml/min using UV detection at 225nm. The described method was linear over a 
concentration range of 5-50µg/ml and 5-25µg/ml for the assay of pioglitazone and 
glimepiride respectively. The retention times of pioglitazone and glimepiride were found 
to be 4.6 and 7.7min respectively. Results of analysis were validated statistically and by 
recovery studies. The results of the study showed that the proposed RP-HPLC method is 
simple, rapid, precise and accurate, which is useful for routine determination of 
pioglitazone and glimepiride bulk drug in pharmaceutical dosage form. 
E. A. Rathod [71] et al. the present work proposed precise, accurate and validated HPLC 
and UV spectrophotometric methods for estimation of teneligliptin from its tablet dosage 
form. The UV spectrophotometric estimation includes calibration curve. Area under 
curve (AUC) and first order derivative method based on measurement of absorbance at a 
selected wavelengths using UV visible spectrophotometer with 1cm matched quartz cell 
and distilled water as a solvent. All UV spectrophotometric methods obeyed beer’s-
lambert’s law in the concentration range of 10-70µg/ml, with correlation co-efficient 
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value less than 1. The chromatographic separation was achieved by isocratic mode with a 
mixture of methanol: phosphate buffer (pH 7.2) in the ratio of 70:30v/v as the mobile 
phase using shodex C18 column as stationary phase at flow rate of 1ml/min and 
detection wavelength of 244nm. The retention time was found to be 5.753min. The 
percent amount of drug estimated by all developed methods was nearly 100%, found to 
be in good agreement with label claim of marketed tablet formulation. The recovery 
study was carried out at five different levels and results were found to be satisfactory. 
The validation parameters like accuracy, precision, ruggedness, linearity and range were 
studied for all the developed methods were found to be within the limits. 
K.P.R.Chowdary[72] et al. the stability indicating RP-HPLC method has been developed 
and validated for simultaneous estimation of metformin hydrochloride and teneligliptin 
in bulk and dosage forms. The involves separation on YMC C18 column 
(150mm×4.6mm×5µm particle size). The optimized mobile phase consists of phosphate 
buffer (pH 3) and acetonitrile (80:20 v/v) with a flow rate of 0.8ml/min and UV 
detection at 220nm. Retention time was 2.138min (metformin hydrochloride), 2.943 
(teneligliptin), 5.075 pioglitazone. Linearity range was 9.98-600µg/ml (metformin 
hydrochloride), 0.51-24µg/ml (teneligliptin). Accuracy was in the range of 99.41-
100.74% for both drugs. Precision was 0.8% and 0.9% for metformin hydrochloride and 
teneligliptin. LOD and LOQ are 0.72µg/ml and 2.40µg/ml for metformin hydrochloride, 
0.15µg/ml and 0.51µg/ml for teneligliptin. The method developed is sensitive, accurate 
and precise. Retention time and run time were also less and hence the method is 
economical when applied to tablet assay, drug content was within 99.89-100.74% of 
labeled content. Forced degradation studies indicated the suitability of the method for 
stability studies. 
Sohan S. Chitlange [73] et al. the simple, accurate precise and economical HPTLC and 
UV method has been developed and validated for the estimation of teneligliptin 
hydrobromide hydrate (THH) in bulk and tablet dosage form. The chromatographic 
method employed pre-coated silica gel 60F₂₂₂ plates using toluene: methanol: 
triethylamine (8:2:0.2 v/v/v) as mobile phase. The plates were developed to a distance of 
8.0cm at ambient temperature. Experimental condition such as band size, chamber 
saturation time, migration of solvent front, slit width, etc were critically studied and the 
optimum condition were selected. A TLC scanner set at 254nm was used for direct 
Review of literature 
 
Dept. of Pharm. Analysis, K.M.C.H College Of Pharmacy  34 
 
evaluation of the chromatograms in reflectance/absorbance mode. The system was found 
to give good result for teneligliptin at Rf 0.51. The calibration plot was found to linear 
between concentrations range 0.5-3µg/ml band and r²=0.9993. Method was validated as 
sper ICH guidelines. In stability testing, teneligliptin was found susceptible to alkali 
hydrolysis and oxidative degradation. Because the method could effectively separate the 
drug from its degradation products, it can be used stability indicating method. A UV 
spectrophotometric method was also developed using methanol as solvent at wavelength 
at 247nm. Beer’s law was obeyed in the concentration range of 5-50µg/ml and 
r²=0.9997. The proposed method was validated according to the ICH guidelines. 
Shraddha Pawar[74]et al. a gradient method is developed for the quantitative 
determination of impurities of glimepiride and metformin hydrochloride in the combined 
pharmaceutical dosage form. The method is based on high performance liquid 
chromatography (HPLC) on a reverse phase column of waters symmetry C8, 5µm 
4.6×250mm thermo stated at 50˚c, using a mobile phase of pentane sulfonic acid sodium 
salt buffer pH 3.5 and acetonitrile and evaluated for its ability to simultaneously establish 
the level of known impurities in glimepiride and metformin hydrochloride tablets. The 
method shows good resolution between glimepiride sulfonamide (GS), glimepiride 
urethane (GU), glimepiride 3-isomer (GI), metformin related compound A (MA), 
glimepiride (G), metformin hydrochloride (M), unknown impurities and formulation 
excipients of tablets. A gradient program with UV detection at 230nm is used to 
quantitate all components. The developed method is validated in term of specificity, 
linearity and range GS, GU, GI, MA, M and G. Accuracy using spiked level of 
impurities (80% to 120% of the specified limit), precision and ruggedness. Limit of 
quantitation is found to be 1.50µg/ml for M, 0.10µg/ml for G, 0.30µg/ml for MA, 
0.24µg/ml for GS, 0.10µg/ml for GU and 0.22µg/ml for GI. 
 M Suchitra[75]et al. A rabid RP-HPLC method was developed and validated for 
simultaneous estimation of metformin and glimepiride, pioglitazone from pharmaceutical 
dosage forms. A sensitive chromatographic separation was accomplished on C18 column 
(100×4.6mm, 5µ) with mobile these consisting of methanol: phosphate puffer (pH3.6 
adjusted with ortho phosphoric acid) in the ratio of 75: 25 v/v, at a flow rate of 1ml/min 
and monitored at 238nm. The developed method was validated in terms of accuracy, 
precision, linearity and limit of detection, limit of quantification, robustness and solution 
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stability. The proposed method can be used for the routine estimation of these drugs in 
combined pharmaceutical dosage form. 
Shailesh V. Luhar [76] et al. a simple, rapid, precise and accurate reversed phase stability 
indicating RP-HPLC method was developed and validated for the simultaneous 
determination of teneligliptin hydrobromide hydrate from its associated main impurities 
and their degradation products. Separation was achieved on a shisedo C18 column, 5µm, 
250mm×4.6mm i.e. column using a mobile phase consisting of acetonitrile: methanol: 
water (30:40:30 v/v/v) at flow rate of 1.0ml/min and UV detection at 246nm. The drugs 
are subjected to acid hydrolysis, alkaline hydrolysis, oxidative degradation and thermal 
degradation to apply force degradation testing. The linearity of the proposed method was 
investigated in the range of 50-300µg/ml (r²=0.9996). The limit of detection was 
2.78µg/ml and the limit of quantification was 8.45µg/ml respectively. 
Prafulla M Patil [77] et al. a high performance thin layer chromatography method for 
determination of teneligliptin was developed and validated as per ICH guide lines. 
HPTLC separation was performed on aluminium plates precoated with silica gel 
60F₂₂₂ and methanol: toluene: triethylamine (1:3:1% v/v) volume as optimized 
mobile phase at detection wavelength at 245nm. The retardation factor (Rf) value for 
teneligliptin were 0.63 respectively. Accuracy for the marketed formulation teneza was 
found to be 98.31-100.51%. The percent relative standard deviation for repeatability and 
intermediate precision studies was found to be <2%. The propose development HPTLC 
method can be applied for identification and quantitative determination of teneligliptin 
respectively. 
Amina A Abdelal[78]et al. the simple reversed phase high performance liquid 
chromatographic (RP-HPLC) method was developed and validated for the simultaneous 
estimation of rosiglitazone (ROS) and glimepiride (GLM) in combined dosage form and 
human plasma. The separation was achieved using a 150mm×4.6mm i.d., 5µm particle 
size C18 column. Mobile phase containing a mixture of acetonitrile and 0.02M 
phosphate buffer of pH 5 (60:40 v/v) was pumped at a flow rate of 1ml/min. UV 
detection was performed at 235nm using nicardipine as an internal standard. The method 
was validated for accuracy, precision, specificity, linearity and sensitivity. The developed 
and validated method was successfully used for quantitative analysis. The 
chromatographic analysis time was approximately 7min per sample with complete 
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resolution of ROS (Rt =3.7min), GLM (Rt =4.66min) and nicardipine (Rt =6.37min). 
Validation studies were performed according to ICH guidelines. 
K. Neelima [79] et al. the simple, sensitive, linear, precise and accurate method by 
gradient reversed phase high performance liquid chromatography for the simultaneous 
estimation on metformin (MET), voglibose (VOG) and glimepiride(GLM) in bulk and in 
their combined tablet dosage form. The separation of the three drugs was based on the 
use of inertsil ODS 3V (150×4.6mm, i.e. 5µm) column in a gradient mode. Mobile phase 
consisted of 0.02M phosphate buffer adjusted to pH 2.5 using dilute orthophosphoric 
acid (solvent A) and acetonitrile (solvent B) was set with gradient programming for 
18min and was delivered at 1ml/min flow rate and effluents are achieved with variable 
wavelength, photodiode array detector at 230nm. The retention time of MET, VOG and 
GLI were found to be 2.423, 8.191 and 11.708 respectively. The percentage assay of 
MET, VOG and GLI at concentration ranges of 200-600µg/ml, 0.08-0.24µg/ml and 0.8-
2.4µg/ml with the regression coefficient of 0.999 for all the three drugs precise with 
(%relative standard deviation <2). The limit of detection MET, VOG and GLI was found 
to be 0.05µg/ml, 0.004µg/ml, 0.002µg/ml and limit of quantification for MET, VOG and 
GLI was found to be 1.5µg/ml, 0.012µg/ml and 0.006µg/ml respectively. 
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                                                          3. DRUG PROFILE 
TENELIGLIPTIN HYDROBROMIDE HYDRATE: [80-83] 
1. Chemical profile 
Chemical name/ IUPAC name       : {(2s,4s)-4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-                                 
                                                          yl)-1-piperazinyl)-2-pyrrolidinyl)-3-                                                                           
                                                          thiazolidinyl hydrobromide,(2:5),hydrate. 
      Molecular formula                         :( C₂₂H₂₂N₂OS) 2.5HBr.xH₂O 
Molecular mass                              : 1275.74 g/mol 
Molecular structure                        : 
  
 
                   Fig. 3: Structure of teneligliptin hydrobromide hydrate 
2. Pharmacokinetic data 
      Bioavailability                              : 63-85% 
Protein Binding                            : 78-80% 
Metabolism                                  : CYP3A4, a cytochrome P450 isoenzyme andflavin  
                                                             Containing monooxygenases (FMO1 and FMO3)  
                                                             Play Major roles in the metabolism of teneligliptin. 
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     Biological half life                         : 8.43-24.2 hrs 
     Excretion                                       : kidney (34.4%) renal (65.6%) 
     Route of administration                : Oral 
    Solubility                                       : DMSO, methanol, water 
3.  Mechanism of  action                         
        Teneligliptin inhibits human dipeptidyl peptidase-4 (DPP-4) enzyme activitywith 
the IC₂₂=1 nM, more than 150 fold selectivity against DPP-8 and DPP-9 which 
Suggested little of target skin lesion side effect.                                       
4. Dosing  
   Adult dose:   the usual adult dosage is 20mg of teneligliptin orally administered 
once a daily. 
5. Side effects 
 Hypoglycemia 
 Constipation  
 Feeling of abdomen enlarged 
 Abdominal discomport 
 Nausea 
 Abdominal pain 
 Meteorism  
 Eczema  
 Rash 
 Pruritus  
 Dermatitis  
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  GLIMEPIRIDE [84-87] 
1. Chemical profile 
 Chemical name/ IUPAC name      : 3-ethyl-4-methyl-2-oxo-N-(2-{4-[({[(1r,4r)-4-     
                                                          methylcyclohexyl]-c-hydroxycarbonimidoyl}            
                                                          amino)sulfonyl]phenyl}ethyl)-2,5-dihydro-1H-   
                                                           pyrrole-  1-carboximidic acid 
Molecular formula                           : C₂₂H₂₂N₂O₂S 
Molecular mass                               : 490.617 g/mol 
Molecular structure                         : 
 
Fig. 4:  Structure of glimepiride 
2. Pharmacokinetic data 
Bioavailability                          : 100% 
Protein binding                         : 99.5% 
Metabolism                               : complete hepatic (1st stage through CYP2C9) 
Biological half-life                    : 5-8 hrs 
Excretion                                   : urine (60%) feces (40%) 
Routes of administration           : oral 
Solubility                                   : soluble in ethanol, DMSO, methanol and water 
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3. Mechanism of action 
       Glimepiride acts as an insulin secretagogue. It lowers blood sugar by stimulating the 
release of insulin by pancreatic beta cells and by inducing increased activity of 
intracellular insulin receptors. 
       Not all secondary sulfonylureas have the same risks of hypoglycemia. 
Glibenclamide (glyburide) Is associated with an incidence of hypoglycemia of up to 20-
30%to as low as 2% to 4% with glimepiride. 
4. Dosing 
Adult dosage: The recommended starting dose 1mg or 2mg taken once per day with 
breakfast or the first main meal of the day                           
Child dosage: glimepiride is not recommended for people under 18 years old because it 
may affect body weight and cause low blood sugar. 
 
5. Side effects 
                     Low blood sugar level symptoms may include: 
 Trembling or shaking 
 Nervousness or anxiety 
 Irritability 
 Sweating  
 Dizziness  
 Nausea  
 Weakness 
 Weight gain 
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                                        4. AIM AND OBJECTIVES  
  For the simultaneous estimation of drugs present in the multi-component dosage forms, 
HPLC and HPTLC methods are considered to be most suitable. These methods are 
powerful, extremely precise, accurate, sensitive, specific, linear and rapid in analyzing 
the sample. The chromatographic methods was found to be most suitable than the other 
methods, due to its very high sensitivity. 
    The present study is to develop and validate RP-HPLC and HPTLC methods for the 
identification and quantification by simultaneous estimation of teneligliptin 
hydrobromide hydrate and glimepiride in tablet dosage form. 
    From the extensive literature survey revealed several methods for estimation of 
individual drugs. There is no RP-HPLC and HPTLC methods were reported for the 
simultaneous estimation of teneligliptin hydrobromide hydrate and glimepiride in 
combined dosage form. The proposed methods were lacking the ICH standards. 
            So the major objectives of the present study are; 
 To reduce the flow rate as compared with previously reported method in 
literature. 
 To carry out simultaneous estimation by using different chromatographic 
conditions. 
 To develop and validate a HPLC and HPTLC method for the 
simultaneous estimation of the drug substances. 
         Based on the above facts, RP-HPLC and HPTLC methods were developed for the 
simultaneous estimation of teneligliptin hydrobromide hydrate and glimepiride.  
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                                             5. PLAN OF WORK 
    The work plan was to develop RP-HPLC and HPTLC methods for the simultaneous 
estimation of teneligliptin hydrobromide hydrate and glimepiride. 
HPLC and HPTLC: 
          The work plan was divided into two phases. 
Phase I: 
Optimization of chromatographic conditions 
 Selection of wavelength 
 Selection of initial separation conditions 
 Selection of mobile phase (pH, peak modifier, solvent strength, ratio and flow 
rate) 
 Nature of the stationary phase 
 Selection of separation method  
Phase II: 
Validation of the method 
        The developed method were proposed to be validated using the various validation 
parameters such as, 
 Accuracy 
 Precision 
 Inter day 
 Intraday 
 repeatability 
 Linearity 
 Limit of detection 
 Limit of quantification 
 Robustness 
 Ruggedness 
 System suitability 
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                                     6. METHODOLOGY 
HPLC METHOD DEVELOPMENT 
MATERIALS AND INSTRUMENTS USED 
1) Drug standard and sample 
             Teneligliptin hydrobromide hydrate and Glimepiride drug (pure) was received as 
a gift sample from micro labs Ltd Bangalore. 
Tablet sample were selected for the method development 
Each film coated tablet contains: 
 Teneligliptin hydrobromide hydrate: 20mg 
 Glimepiride                                      :  1mg 
2) Chemicals and solvents 
 Acetonitrile HPLC grade 
 Methanol HPLC grade 
 Ortho phosphoric acid AR grade 
 HPLC grade water was prepared by using Millipore MilliQ water 
purification system 
3) Instruments  
 Elico pH meter L1 127 
 SPD-M20A prominence diode array detector 
 Shimadzu 1600LC-UV spectrophotometer 
 Sonica ultrasonic cleaner 
 Solvent filtration unit- Millipore  
 Shimadzu electronic balance AY 220 
 Shimadzu prominence HPLC 
 Pump- Prominence LC- 20AT 
 Column- Phenomenex Luna 5µ C18 (2) 100A, (250mm×4.6×i.d. 
5µ) 
 Inject- Rheodyne 7725i with 20µl loop 
 Detector- Photo diode array detector 
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METHOD DEVELOPMENT AND OPTIMIZATION OF CHROMATOGRAPHIC 
CONDITION 
             The present work is the development of the RP-HPLC method for the 
simultaneous estimation of Teneligliptin hydrobromide hydrate and Glimepiride in tablet 
dosage form. 
a) Selection of wavelength: 
       The wavelength for the analysis of Teneligliptin hydrobromide hydrate and 
Glimepiride was selected by injecting several times of mixed standards of 10 µg/ml of 
Teneligliptin hydrobromide hydrate and 10 µg/ml of Glimepiride, for optimum detection 
of both the drugs. Since both Teneligliptin hydrobromide hydrate and Glimepiride have 
shown maximum absorbance at 246nm, finally which was selected as an optimum wave 
length for the estimation method. 
b) Selection of method for separation: 
          Proper selection of the method depends upon the nature of the sample 
(ionic/ionisable/neutral molecule), its molecular weight and solubility. The drug selected 
in the present study is polar in nature and hence the reverse phase HPLC was selected for 
the initial separations because of its simplicity and suitability. 
c) Initial chromatographic conditions: 
 Chromatographic condition: 1 
  Stationary phase  : Phenomenex C18 column 
  Mobile phase                       : Solvent A – water 
                           Solvent B - acetonitrile 
  Solvent ratio                        : 50: 50 (A: B) 
  Detection Wavelength         : 246 nm 
  Flow rate                             : 1.0 ml/min                                             
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   Sample size               : 20 µl 
   Temperature                        : 25oC 
 At the above chromatographic condition Teneligliptin hydrobromide hydrate and 
Glimepiride was eluted at a retention time of 7.33 min and 13.32 min. The peaks 
observed were broad and asymmetric hence not selected further for method development. 
Chromatographic Condition – 2 
Stationary phase         : Phenomenex C18 column 
Mobile phase                      : Solvent A – water (pH adjusted to 4.0 with Orthophosphoric  
                                              acid) Solvent B - acetonitrile 
Solvent ratio                       : 50: 50 (A: B) 
Detection Wavelength       : 246 nm 
Flow rate                            : 1.0 ml/min                                             
Sample size                      : 20 µl 
Temperature                       : 25ºC 
 Teneligliptin hydrobromide hydrate was eluted at retention time of 6.20 min with 
peak splitting, Glimepiride at retention time 8.35 min with peak splitting hence not 
selected further for method development.  
Chromatographic Condition – 3 
Stationary phase         : Phenomenex C18 column 
Mobile phase                     : Solvent A – water (pH adjusted to 4.0 with Orthophosphoric   
                                              acid) Solvent B - acetonitrile 
Solvent ratio                       : 30: 70(A: B) 
Detection Wavelength        : 246 nm 
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Flow rate                            : 1.0 ml/min                                             
Sample size                      : 20 µl 
Temperature                       : 25oC 
 Teneligliptin hydrobromide hydrate was eluted at retention time 6.33 min with 
peak tailing and Glimepiride was eluted at 12.33 min. Peak tailing was observed hence 
not selected.  
Chromatographic Condition – 4 
Stationary phase        : Phenomenex C18 column 
Mobile phase                     : Solvent A – water (pH adjusted to 3.0 with Orthophosphoric  
                                              acid) Solvent B - acetonitrile 
Solvent ratio                       : 40: 60 (A: B) 
Detection Wavelength        : 246 nm 
Flow rate                             : 1.0 ml/min                                             
Sample size                       : 20 µl 
Temperature                       : 25oC 
 Teneligliptin was eluted at retention time 6.44 min and Glimepiride was eluted at 
10.2 min with peak broadening hence not selected.  
 
Chromatographic Condition – 5 
Stationary phase         : Phenomenex C18 column 
Mobile phase                      : Solvent A – water (pH adjusted to 3.5 with Orthophosphoric  
                                               acid)  Solvent B - acetonitrile 
Solvent ratio                       : 30: 70 (A: B) 
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Detection Wavelength        : 246 nm 
Flow rate                             : 1.0 ml/min                                             
Sample size                        : 20 µl 
Temperature                         : 25oC 
 Teneligliptin hydrobromide hydrate was eluted at retention time 6.44 min and 
Glimepiride was eluted at 12.2 min with peak broadening hence not selected.  
OPTIMIZATION OF SEPARATION CONDITIONS 
Effect of pH: 
Table 4: Effect of PH 
          Drug  pH Retention time 
(min) 
Observation 
 
TENE 
4.0 6.2 Fronting 
3.5 6.4 Tailing effect 
3.0 5.8 Good 
 
GLI 
4.0 12.3     Peak broadening 
3.5 12.2 Splitting 
3.0 9.4  Good 
 
Effect of ratio of mobile phase: 
        The mobile phase of acetonitrile: phosphate buffer in various ratios, 50:50, 60:40, 
70:30. 65:35 and 80:20 were tried and the chromatograms were recorded at 246nm with 
a flow rate of 1ml/min. At the ratio of 65:35 of acetonitrile: phosphate buffer was 
selected (pH adjusted with 3.0 with orthophosphoric acid) as an ideal ratio for the 
estimation of Teneligliptin hydrobromide hydrate and Glimepiride. 
       The standard solution was chromatographed for 20min, using 65% acetonitrile and 
phosphate buffer solution of different pH ranges 4.0, 3.5, 3.0 at 246nm, the mobile has 
the flow rate of 1ml/min using phenomenex C18 column as stationary phase for 
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Teneligliptin hydrobromide hydrate and Glimepiride determination and pH 3.0 was 
selected as the ideal pH for the separation of the drugs. 
Table 5: Effect of mobile phase 
          Drug    Ratio (%v/v)  Retention time 
(min) 
   Observation  
 
      TENE 
       50:50              4.6      Broad 
       60:40              6.3     Tailing effect 
       65:35              5.8        Good  
 
     GLI 
       50:50              8.5      Little broad 
       60:40              12.4        Splitting  
       65:35              9.4         Good  
 
 
Effect of flow rate: 
      Keeping the mobile phase ratio 65:35 (acetonitrile: phosphate buffer) were used and 
the chromatograms were recorded at a flow rate 1ml/min. At this flow rate, the peaks 
were sharp with good resolution. So 1ml/min was kept constant for the analysis (flow 
rate 0.9ml/min, 1.1ml/min up to 1.3ml/min were also tried, but did not give any 
satisfactory results). 
 
 
Mobile phase: 
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      Prepare a filtered and degassed mixture of acetonitrile: phosphate buffer pH adjusted 
to 3.0 with orthophosphoric acid (65:35) was used as a mobile phase. 
Fixed chromatographic conditions: 
Stationary phase             : Phenomenex C18 column 
Mobile phase                     : Solvent A – phosphate buffer (pH adjusted to 3.0 with 
                                                  Orthophosphoric acid) solvent B- acetonitrile                               
Solvent ratio                            : 35:65 (A: B) 
Detection Wavelength            : 246 nm 
Flow rate                                 : 1.0 ml/min                                             
Sample size                : 20 µl 
Temperature                           : 25oC 
 Teneligliptin was eluted at 5.8 min and Glimepiride was eluted at 9.41 min with 
perfect peak properties and hence selected for further studies.  
 
Estimation of Teneligliptin hydrobromide hydrate and Glimepiride: 
     Estimation of Teneligliptin hydrobromide hydrate and Glimepiride in tablet dosage 
forms by RP-HPLC method was carried out by standard calibration method. 
Preparation of standard solution: 
     Weighed accurately 10 mg of Teneligliptin hydrobromide hydrate and was dissolved 
in methanol and made up to 10ml. 0.1ml of this stock solution was diluted to 10ml to get 
solution A. Similarly 1mg of Glimepiride was dissolved in methanol and made up to 
20ml and 0.1ml of this stock solution was diluted to 10ml to get a solution B. 
        Mix 0.1ml of each stock solution in 10ml standard flask made up to 10ml methanol 
with final concentration solution of Teneligliptin hydrobromide hydrate and Glimepiride 
respectively. 
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      Aliquots of mixed standard solutions of 0.05ml, 0.10ml, 0.15ml, 0.20ml, 0.25ml of 
TENE and GLI were diluted in mobile phase to get a final concentration of 5, 10, 15, 
20, 25 μg/ml of Teneligliptin hydrobromide hydrate and 0.25, 0.5, 0.75, 1, 1.25 μg/ml of 
Glimepiride. All the solutions were sonicated for 20 minutes before injection. 
Preparation of sample solution: 
        Twenty tablets of each containing Teneligliptin hydrobromide hydrate-20mg, and 
Glimepiride 1mg were weighed, and crushed into fine powder. A quantity of powder 
equivalent to 20mg of Teneligliptin was weighed and dissolved in 5 ml of mobile phase 
(4:6) and sonicated for 15 min. Then the volume was made up to 10 ml with mobile 
phase ratio and filtered through whatmann filter paper. The aliquots of 0.05ml, 0.10ml, 
0.15ml, 0.20ml, 0.25ml of TENE and GLI the final sample solution was prepared. 
Recording chromatogram 
      After optimization of chromatographic conditions mentioned above, a study baseline 
for about 30 min was recorded. After the stabilization of the baseline, 100µg/ml of the 
standard solutions were injected and chromatograms were recorded until the 
reproducibility of the peak areas were found satisfactory and finally 10µg/ml of the 
standard solutions of the individual samples of Teneligliptin hydrobromide hydrate and 
Glimepiride were recorded. The standard solution containing 5-25 μg/ml of Teneligliptin 
hydrobromide hydrate and 0.25-1.25 μg/ml of Glimepiride were injected and 
chromatograms were recorded. 
       Retention time of Teneligliptin hydrobromide hydrate and Glimepiride were found 
to be 5.8 and 9.4min respectively Fig.5. 
       The procedure was repeated as both sample and standard solution. The peak purity, 
UV spectrum and peak profile of Teneligliptin hydrobromide hydrate was shown in Fig. 
14, 15 and 16 and foe Glimepiride was shown in Fig. 17, 18 and 19 respectively. 
     Calibration curves were plotted using peak area against concentration of 
corresponding standard solutions. Peak areas of the sample chromatograms were 
recorded and the amount of teneligliptin hydrobromide hydrate and glimepiride were 
calculated. 
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VALIDATION OF THE METHOD 
       Validation is the process of establishing documented evidence, which provides a 
high degree of assurance that a specific activity will consistently produce a desired result 
or product meeting its predetermined specifications and quality characteristics. 
Significance of method validation: 
       The quality of analytical data is a key factor in the success of a drug development 
program. The process of method development and validation has a direct impact on the 
quality of these data. 
     Analytical validation is a very important feature of any package of information 
submitted to international regulatory agencies in support of new product marketing or 
clinical trial applications. A through method development can almost rule out all 
potential problems, at the same time, a through validation programme can address the 
most common ones and provide assurance to the intended purpose (can be used with 
100% confidence). In other words, a through validation can fulfil all the technical and 
regulatory objectives. A direct consequence and most significant out come from any 
method validation exercise is the development of meaningful specifications can be 
predicted upon the use of validated analytical procedures that can assess changes in drug 
substance or drug product during its life time. 
      Analytical characteristics listed below may not be applicable to every test procedure 
or every particular material. It will mostly depend on the purpose of which the procedure 
is required, however, these following aspects of validation should be given due 
importance.  
a) Accuracy: 
        Accuracy method was determined by recovery experiments. The reference standards 
of the respective drug were added to the sample solution, (10 μg/ml of Teneligliptin 
hydrobromide hydrate and 0.50 μg/ml of Glimepiride) at the level of 50%, 100% and 
150%. These were further diluted by procedure as followed in the estimation of 
formulation. The concentration of drug present in the resulting sample solution was 
determined by using assay method. 
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b) Precision: 
         The precision of the developed method was determined in terms of intermediate 
precision (intra-day and inter-day) and repeatability. Teneligliptin hydrobromide hydrate 
(15 μg/ml) and Glimepiride (0.75 μg/ml) were analysed in six times during the same day 
(intra-day precision) and three consecutive days (inter-day precision). The %RSD values 
of intra-day, inter-day and repeatability studies for Teneligliptin hydrobromide hydrate 
and Glimepiride showed that the precision of the method was satisfactory. 
c) Linearity and range: 
         From the standard stock solutions, a suitably mixed standard solution was prepared. 
Teneligliptin hydrobromide hydrate and Glimepiride were found to be linear in the range 
of 5 to 25 μg/ml and 0.25 to 1.25 μg/ml respectively. The solutions were examined by 
the assay procedure. The calibration curve was plotted by using peak area Vs 
concentration of the standard solution. From the calibration curve, the slope and intercept 
were calculated. 
d) Limit of detection (LOD) and Limit of quantification (LOQ): 
            The LOD and LOQ was separately determined and reported in Table 13, based 
on the calibration curve of standard solution. The residual standard deviation of the 
regression line or the standard deviation of y- intercepts of regression lines may be used 
to calculate LOD and LOQ. LOD= 3.3 × σ/S  and LOQ= 10 × σ/S, where, σ is the 
standard deviation of y- intercepts of regression line and S is the slope of the calibration 
curve. 
          LOD is the smallest concentration of the analyte that can be detected and gives the 
measurable response (signal to noise ratio of 3). The signal to noise ratio were performed 
by comparing by measured signal of known low concentration of drug. LOQ is the 
smallest concentration of analyte that can be accurately quantified (signal to noise ratio 
10). 
e) Specificity: 
        The specificity of the RP-HPLC method was determined by complete separation of 
Teneligliptin hydrobromide hydrate and Glimepiride with parameters like retention time 
(Rt), resolution (Rs) and tailing factor (T), peak purity curve and peak purity index. 
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Tailing factor for peaks of teneligliptin hydrobromide hydrate and glimepiride less than 
2% and resolution was satisfactory. The peaks obtained for were sharp and have clear 
baseline separation. The peak purity studies were performed to prove that the method is 
specific in nature. 
f) Ruggedness: 
         It expresses the precision within laboratory variations like different days, different 
analyst and different equipments. Ruggedness of the method was assessed by spiking the 
standard concentrations of Teneligliptin hydrobromide hydrate (15 μg/ml) and 
Glimepiride (0.75 μg/ml), 6 times in two different days with different analyst. 
g) Robustness: 
          In order to demonstrate the robustness of the method, the following optimized 
conditions were slightly varied. 
1) ± 2% in ratio of acetonitrile in mobile phase, 
2) ± 0.2ml of flow rate 
3) ± units in the pH of buffer 
4) ± 2nm wavelength 
        The separation factor, retention time and peak symmetry were than calculated. The 
deviation among the results obtained is well within the limits. Hence the method is 
robust. 
h) System suitability studies: 
         The system suitability studies were carried out as specified in ICH. These 
parameters include number of theoretical plates, HETP, column efficiency, resolution 
and capacity factor. 
 
 
HIGH PERFORMNCE THIN LAYER CHROMATOGRAPHY (HPTLC) 
METHOD DEVELOPMENT 
a) Drug standard and sample: 
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       Teneligliptin hydrobromide hydrate and Glimepiride drug (pure) was received as a 
gift sample from micro labs Ltd Bangalore.  
Tablet sample were selected for the method development 
Each film coated tablet contains: 
 Teneligliptin hydrobromide hydrate: 20mg 
 Glimepiride                                      :  1mg 
b) Chemicals and solvents used: 
          The selected solvent must give some ideal properties like, the drug should be 
stable in the selected solvent. Hence methanol was selected as the solvent for the drug. 
Other solvents used were of analytical grade. 
c) Selection of detection wavelength: 
         The sensitivity of the HPTLC is depending on the wavelength selected and the UV 
detector. An ideal wavelength is the one that gives maximum absorbance and good 
response for the drug detected at lower concentration also. The drugs were scanned under 
UV spectrum between 200-400 nm and the detection was carried out in absorbance mode 
at 246 nm. It was selected as detection wavelength for the selected mobile phase. 
d) Selection of mobile phase: 
      Various mobile phases at various ratios were tried for the separation of the drugs. 
The Rf values were calculated for the methods tried and a mobile phase with optimum 
separation was selected. 
 
 
 
Table 6: various mobile phase system were tried for optimization of mobile phase 
Mobile Phase Rf value Observation 
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GLI TENE 
Toluene: Chloroform: Ethanol: Diethyl 
amine (4:4:1:1 v/v/v/v) 
0.28 0.59 Asymmetrical 
peak 
Toluene: Chloroform: Ethanol: diethyl amine 
(4.5:3.5:1:1 v/v/v/v) 
0.43 0.69 Broad peak 
Toluene: Chloroform: Ethanol (3:6:1 v/v/v) 0.35 0.59 Broad peak 
Toluene: Methanol: Triethyl amine (2:2:1 
v/v/v) 
0.59 0.64 Merged peak 
Toluene: Methanol: Triethyl amine (1:3:1 
v/v/v) 
0.49 0.60 Symmetrical peak 
 
Optimization  
Fixed experimental parameters 
Injection   :     Linomat 5  
Detection   :     CAMAG TLC scanner 
Information:  
Chamber type               :    Twin trough chamber 20x10cm 
Stationary phase   :    Pre - coated silica gel GF aluminium sheets TLC  plate     
            Mobile phase                 :     Methanol: Toluene: Triethyl amine (1:3:1v/v/v) 
Chamber saturation       :        20 min 
Band length                :        6.0 mm   
           Application position        :       10.0 mm 
Solvent front position     :       80.0 mm   
Instrument:  
             Number of track           :       9   
 Position of first track X       :     10.0 mm 
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             Distance between tracks       :      10.0mm  
             Scan start position Y             :      5.0 mm 
             Scan end position Y            :      75.00mm 
             Slit dimensions             :       6.00 x 0.45 mm, micro 
Measurement table: 
             Wavelength              :        246 nm  
 Lamp                                      :          D2  
 Measurement type                  :        Remission  
 Measurement mode                 :        Absorption 
 Optical filter                            :        Second order 
 Detector mode                        :        Automatic 
Preparation of standard solution: 
         Mixed stock standard solution containing 20 mg of TENE and 1mg of GLI in 10 ml 
methanol. Mixed stock standard solution was further diluted with methanol to obtain 
working standard solutions in a concentration range of 2000-20000(ng/spot) for TENE 
and 100-1000 (ng/spot) for GLI. 
Preparation of sample solution: 
        For analysis of tablet dosage form, twenty tablets, each containing 20mg 
Teneligliptin hydrobromide hydrate and 1 mg Glimepiride, were weighed and their 
average weight was calculated. The tablets were finely powdered and powder equivalent 
to 20mg of TENE was accurately weighed and transferred into 10 ml of volumetric flask 
containing 5 ml of methanol, Sonicated for 30 min. The solution was filtered through 
Whattman No 41 filter paper and the residue was washed with methanol. The volume of 
the filtrate was adjusted to 10 ml with the same solvent. This above solution was further 
diluted with methanol to get the concentrations of 4000, 8000and 16000 (ng/spot) for 
TENE and 200, 400 and 800 (ng/spot) for GLI. 
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VALIDATION OF HPTLC METHOD 
a) Accuracy: 
Accuracy of the method was determined by recovery experiments. The reference 
standards of the respective drug were added to the sample solution 8000 (ng/spot) of 
Teneligliptin hydrobromide hydrate and 400 (ng/spot) of Glimepiride at the level of 
50%, 100% and 150%. These were further diluted by procedure as followed in the 
estimation of formulation. The concentrations of the drugs present in the resulting 
sample solution were determined by using assay method.   
b) Linearity and range: 
From the standard stock solutions, a suitably mixed standard solution was 
prepared. Teneligliptin hydrobromide and Glimepiride were found to be linear in the 
range of 2000 to 20000 (ng/spot) and 100 to 1000 (ng/spot) respectively. The solutions 
were examined by the assay procedure. The calibration curve was plotted using peak area 
Vs concentration of the standard solution. From the calibration curve, the slope and 
intercept were calculated.  
c) Precision: 
Precision of the method was determined by: 
Intra-day precision 
Inter-day precision 
Repeatability 
 
 
 
 
a) Intra-day Precision: 
Intra-day precision was found out by carrying out the analysis of the standard 
drug solutions at concentration of 4000-16000 (ng/spot) of TENE and 200-800 (ng/spot) 
of GLI for three times on the same day. The Percentage RSD was calculated. 
b) Inter-day precision: 
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Inter-day precision was found out by carrying out the analysis of the drug 
solution at a concentration of 4000-16000 (ng/spot) of TENE and 200-800 (ng/spot) of 
GLI for three different days and the percentage RSD was calculated. 
c) Repeatability: 
Repeatability of measurement of the peak area was determined by spotting 
8000(ng/spot) TENE and 400 (ng/spot) GLI of drug solution on a pre-coated TLC plate. 
The separated spots were scanned five times without changing the position of the plate 
and the percentage RSD was calculated. 
 d) Limit of Detection (LOD) and Limit of Quantification (LOQ): 
The detection limit of an individual analytical procedure is the lowest amount of 
analyte in a sample which can be detected but not necessarily quantitated as an exact 
value. The quantitation limit of an individual analytical procedure is the lowest amount 
of analyte in a standard which can be quantitatively determined with suitable precision 
and accuracy. The LOD and LOQ were experimentally verified by the known 
concentration of a standard solution of Teneligliptin hydrobromide hydrate and 
Glimepiride until the average response approximately 3 or 10 times the standard 
deviation of the responses for five replicate determinations. 
 
e) Specificity:  
It was observed that other constituent’s presents in the formulation did not 
interfere either with the peak of Teneligliptin hydrobromide hydrate and Glimepiride. 
Therefore the method was specific. The overlay spectrum of the standard Teneligliptin 
hydrobromide hydrate and Glimepiride spots present in the samples were found to be 
similar or overlap. The peak purity of the Teneligliptin hydrobromide hydrate and 
Glimepiride was assessed by comparing the spectra at three different levels, viz. peak 
start, and peak apex and peak end positions of the spot. 
 f) Robustness of the method: 
The robustness of an analytical procedure is a measure of its capacity to remain 
unaffected by small changes in the mobile phase composition, mobile phase volume and 
duration of mobile phase saturation and the effects on the results were examined.  
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g) Ruggedness: 
It expresses the precision within laboratory variations like different days, 
different analyst, and different equipments. Ruggedness of the method was assessed by 
spiking the standard concentrations of TENE 8000 (ng/spot) and GLI 400 (ng/spot), five 
times in two different days with different analyst.  
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                                        7. RESULTS AND DICUSSION 
HPLC 
             A RP-HPLC method was developed for the simultaneous estimation of 
Teneligliptin hydrobromide and Glimepiride in tablet dosage form, which can be 
conveniently employed for routine quality control in pharmaceutical dosage forms. 
Fixed chromatographic conditions: 
Stationary phase                                 : Phenomenex C18 column 
Mobile phase                                     : Solvent A – phosphate buffer (pH adjusted to 3  
                                                             with Orthophosphoric acid) solvent B- acetonitrile          
Solvent ratio                                       : 35:65 (A: B) 
Detection Wavelength                        : 246 nm 
Flow rate                                             : 1.0 ml/min                                             
Sample size       : 20 µl 
Temperature                                       : 25oC 
           Teneligliptin was eluted at 5.8 min and Glimepiride was eluted at 9.41 min with 
perfect peak properties and hence selected for further studies.  
 
 
 
Fig.5: Typical chromatogram obtained for the Teneligliptin hydrobromide hydrate 
and Glimepiride. 
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1. Linearity: 
          Teneligliptin hydrobromide hydrate and Glimepiride were found to be linear in the 
range of 5 to 25 μg/ml and 0.25 to 1.25 μg/ml respectively. 
          The correlation coefficient of Teneligliptin hydrobromide hydrate and Glimepiride 
were found to be 0.998 and 0.996 respectively. The linearity range of Teneligliptin 
hydrobromide hydrate and Glimepiride were shown in Table 7 and 8 respectively. The 
calibration curves were plotted as peak area Vs concentration of the standard solutions 
(Fig. 6 and 7). 
           The calibration graph showed linear response over the range of 5 to 25 μg/ml for 
TENE and 0.25 to 1.25 μg/ml of GLI. The range demonstrates that the method is linear 
outside the limits of expected use. 
 
Table 7: Linearity range of Teneligliptin hydrobromide hydrate 
S.NO Conc. of TENE 
 (μg/ml) 
Peak  area* 
1 
2 
3 
4 
5 
 
 
5 
 
10 
 
15 
 
20 
 
25 
132821 
 
230885 
 
351956 
 
480892 
 
620783 
*mean of five observations 
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Calibration curve of teneligliptin 
      
 
                            Fig.6: Calibration curve of Teneligliptin hydrobromide hydrate 
 
Table 8: Linearity range of Glimepiride 
S.NO Conc. of GLI 
 (μg/ml) 
Peak  area* 
1 
 
2 
 
3 
 
4 
 
6 
0.25 
 
0.5 
 
0.75 
 
1 
 
1.25 
19705 
 
37846 
 
56171 
 
71068 
 
85898 
*mean of five observations 
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Calibration curve of glimepiride 
 
                                  Fig. 7: Calibration curve of Glimepiride 
 
 
Acceptance criteria 
           The results complied with an acceptance criteria since the linearities were found 
to be with in the specified limit of correlation co-efficient ie, 0.99. 
 
 
 
2. Accuracy (Recovery studies): 
          The accuracy of the method was determined by recovery experiments. A known 
quantity of the pure drug was added to the pre-analyzed sample formulation at 50%, 
100% and 150% levels. The recovery studies were carried out 6 times of each level and 
the percentage recovery and percentage relative standard deviation were calculated and 
given in Table 9. The percentage recovery of Teneligliptin hydrobromide hydrate and 
Glimepiride were found to be in the range of 98.83 to 99.83% and 99.60 to 99.90% 
respectively. 
 
 
0
10000
20000
30000
40000
50000
60000
70000
80000
90000
100000
0 0.2 0.4 0.6 0.8 1 1.2 1.4
Pe
ak
  a
re
a
Concentration μg/ml
Calibration curve of glimepiride
Results and discussion 
 
Dept. of pharm. Analysis, K.M.C.H college of pharmacy  64 
 
 
Table 9: Accuracy (Recovery studies): 
Drug Label 
claim 
mg/tab 
Spike 
Level 
(%) 
Amount      
of drug 
added 
(μg/ml) 
Amount of 
drug 
recovered 
(μg/ml) 
Percentage 
Recovery 
(%) 
%RSD* 
  
  
 TENE 
  
  
  20 
 50  15   14.92  98.90  0.40 
100 
  
20 
  
19.8 98.83 0.36 
150 
  
25 
  
24.90 98.93 0.40 
  
  
 GLI 
  
  
 1 
  
  
50 
  
0.75 0.749 99.60 0.27 
100 
  
1 0.98 99.89 0.22 
150 
  
1.25 1.249 99.90 0.28 
*mean of five observations 
 
         From the data obtained, it was observed that the recoveries of standard drugs were 
found to be accurate and within the specified limits. 
 
 
 
 
3. Precision: 
        The precision of the method was determined by studying reproducibility and 
repeatability. The area of drug peaks and percentage relative standard deviation of 
intraday and inter day were calculated and presented in Table 10 and 11. The results 
revealed that the developed method was found to be reproducible in nature. 
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Table 10: Intraday studies 
No. of 
Injection 
Conc.   of 
TENE 
(μg/ml) 
 
   Peak  
   Area* 
 
% RSD* 
 
Conc.   of 
GLI 
(μg/ml) 
 
Peak 
Area* % RSD* 
       6  15  353277.0  0.39  0.75  56880.0  0.25 
*mean of five observations 
 
Acceptance criteria  
       The results obtained complied with acceptance criteria since percentage relative 
standard deviation of peak areas of TENE and GLI were found to be with in the limit ie, 
NMT 2%. 
 
Table 11: Inter day studies 
Day 
Conc. Of 
TENE 
(μg/ml) 
 
 
Peak 
Area* 
% RSD* 
Conc.   of 
GLI 
(μg/ml) 
 
 
Peak 
Area* 
% RSD* 
     
DAY1  15  353270.5  0.36  0.75  56532.00  0.23 
 
DAY2  15 353112.80  0.35  0.75  56840.30  0.24 
 
DAY3  15  353412.5  0.35  0.75  56896.20  0.25 
*mean of five observations 
 
 
Acceptance criteria 
             The results obtained complied with acceptance criteria since percentage relative 
standard deviation of peak areas of TENE and GLI were found to be with in the limit ie, 
NMT 2%. 
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Table 12: Repeatability 
Conc. of 
TENE 
(μg/ml) 
 
Peak Area* 
 
% RSD* 
Conc. of  
GLI 
(μg/ml) 
 
Peak Area* 
 
% RSD* 
  
15 
  
353277.0 
  
0.39 
  
0.75 
  
56880.16 
  
0.26 
*mean of five observations 
 
Acceptance criteria 
            The results obtained complied with acceptance criteria since percentage relative 
standard deviation of peak areas of TENE and GLI were found to be with in the limit ie, 
NMT 2%. 
 
4. LOD and LOQ: 
             The LOD is the smallest concentration of the analyte that gives a measurable 
response (signal to noise ratio of 3.3). The LOQ is the smallest concentration of the 
analyte, which gives response that can be accurately quantified (signal to noise ratio of 
10). 
 
Table 13: LOD and LOQ 
Parameter TENE (μg/ml) GLI (μg/ml) 
LOD 1.320 0.903 
LOQ 3.561 2.736 
 
 
 
5. Ruggedness: 
           The sample was analyzed by a different chemist and same instruments on 
different days have been performed. The method is rugged since the deviation among the 
results obtained by two chemists on a different day was within the limits i.e., NMT 2%. 
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Table 14: Ruggedness studies 
Drug name Concentration 
(µg/ml) 
Peak area* %RSD* 
Day-1 analyst-1 
TENE 15               357245.00  0.82 
GLI 0.75               56247.16 0.64 
                                                                Day-2 analyst-2 
TENE 15   358142.5 0.79 
GLI 0.75               56392.00 0.59 
*mean of five observations 
 
6. Robustness: 
            The robustness studies were performed for the standard solutions and were 
presented in Table 15. The assay values were within the limits thus the developed 
method is robust. 
Table 15: Robustness studies 
Parameters Modifications TENE Recovery (%) GLI Recovery (%) 
pH 
3.5 98.96 98.53 
4.0 99.92 99.84 
Detection 
wavelength (nm) 
244 99.89 99.33 
248 98.79 98.92 
Flow rate 
(ml/min) 
1.1 99.93 99.93 
0.9 98.76 98.89 
 *mean of five observations 
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7. System suitability studies: 
           The system suitability studies were performed for the standard solutions and are 
presented in Table 16. The values obtained demonstrate the system suitability for the 
analysis of the above drug combination. 
 
Table 16: System suitability studies 
Parameters TENE GLI 
No. Of Theoretical Plates 5069 5909 
Tailing Factor 0.98 1.02 
HETP 20.27 23.63 
LOQ 3.57 ng/ml 2.73 ng/ml 
LOD 1.32 ng/ml 0.90 ng/ml 
Resolution              3.52 
K 4.17 2.83 
 
8. Analysis of formulation: 
         The percentage of drug in formulation, mean and relative standard deviation were 
calculated. The result of analysis showed that the amount of drug present in the 
formulation is in good correlation with the label claim of the formulation. 
 
Table17: analysis of formulation 
Formul
ation 
Labelled amount 
(mg) 
Amount Found 
(mg) 
Percentage assay 
(%) %R.S.D* 
 
 Tablet  
   
 TENE 
 
 GLI 
  
TENE 
  
GLI 
  
TENE 
  
GLI 
  
TENE 
  
GLI 
      20 
  
1 
  
  19.8  0.98 
  
98.80 
  
99.68 
  
0.23 
  
0.26 
  
*mean of five observations 
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          Fig. 8: Chromatogram for TENE 5 μg/ml and GLI 0.25 μg/ml (standard) 
                Fig.9: Chromatogram for TENE 10 μg/ml and GLI 0.50 μg/ml (standard) 
 
              Fig.10: Chromatogram for TENE15 μg/ml and GLI 0.75 μg/ml (standard) 
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                Fig.11: Chromatogram for TENE 20 μg/ml and GLI 1.00 μg/ml (standard) 
 
                        Fig.12: Chromatogram for TENE 25 μg/ml and GLI 1.25 μg/ml (standard) 
 
Fig.13: Chromatogram of   TENE and GLI 15 µg/ml and 0.75 µg/ml (sample solution) 
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                                      Fig.14: UV spectrum of Teneligliptin hydrobromide hydrate 
 
 
Fig.15: Purity curve of Teneligliptin hydrobromide hydrate 
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Fig.16: Peak profile of Teneligliptin hydrobromide hydrate 
 
 
                                                        Fig.17: UV spectrum Glimepiride 
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     Fig.18: Peak purity of Glimepiride 
 
  
Fig.19: Peak profile of Glimepiride 
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HPTLC 
       A HPTLC method was developed for the simultaneous estimation of Teneligliptin 
hydrobromide hydrate and Glimepiride in tablet dosage forms, which can be 
conveniently employed for routine quality control in pharmaceutical dosage forms. 
 
1. Linearity: 
           Teneligliptin hydrobromide hydrate and Glimepiride were found to be linear in 
the range of 2000 to 20000 (ng/spot) and 100 to 1000 (ng/spot) respectively. 
 
            The correlation coefficient of Teneligliptin hydrobromide hydrate and 
Glimepiride were found to be 0.9967 and 0.9938. The linearity range of Teneligliptin 
hydrobromide hydrate and Glimepiride were shown in Table 18 respectively.  
 
           The calibration curves were plotted as peak area Vs concentration of the standard 
solutions (Fig.20 and 21). 
 
           The calibration curves graph shows that linear response was obtained over the 
range of concentrations used in the assay procedures. The range demonstrates that the 
method is linear outside the limits of expected use. 
Table 18: Linearity range of Teneligliptin hydrobromide hydrate and glimepiride 
Concentration 
(ng/spot) 
TENE 
Concentration 
( ng/spot) 
GLI 
 
Rf  value 
 
Peak 
area* 
 
Rf  
value 
 
Peak 
area* 
2000 0.58 3020.3 100 0.46 2280.2 
4000 0.58 5347.2 200 0.46 4203.5 
8000 0.60 9932.4 400 0.46 7156.5 
16000 0.59 17696.5 800 0.47 12402.3 
20000 0.60 21686.2 1000 0.48 15382.1 
*mean of five observations 
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Acceptance criteria 
       The results complied with an acceptance criteria since coefficient of correlation was 
found to be with in the limit i.e., NLT 0.99. 
 
Calibration curve of teneligliptin 
 
                     
              Fig.20: Calibration curve of Teneligliptin hydrobromide hydrate 
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Calibration curve of glimepiride 
 
                               
                                 Fig.21: Calibration curve of Glimepiride 
 
 
 
2. Accuracy (Recovery studies): 
            The accuracy of the method was determined by recovery experiments. A known 
quantity of the pure drug was added to the pre-analyzed sample formulations at 50%, 
100% and 150% levels. The recovery studies were carried out 6 times of each level and 
the percentage recovery and percentage relative standard deviation were calculated and 
given in Table 19. The percentage recovery of Teneligliptin hydrobromide hydrate and 
Glimepiride found to be in the range of 99.56 to 99.87% and 99.64 to 99.92% 
respectively. 
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Table 19: Accuracy (Recovery studies) 
 
Drug 
Amount 
present 
Spike 
Level 
(%) 
Amount      
of drug 
added 
(ng/spot) 
Amount of 
drug 
recovered 
(ng/spot) 
Percentage 
Recovery 
%RSD* 
TENE 8000 
50 4000 3989.7 99.65 0.75 
100 8000 7998.9 99.56 0.64 
150 12000 11988.7 99.87 0.88 
GLI 
 
      400 
 
 
50 200 199.7 99.78 1.113 
100 400 398.5 99.64 1.012 
150 600 598.7 99.92 1.203 
*mean of five observations 
            
      From the data obtained, it was observed that the recoveries of standard drugs were 
found to be accurate and within the specified limits. 
 
 
 
3. Precision: 
        The precision of the method was determined by studying reproducibility and 
repeatability.  The area of drug peaks and percentage relative standard deviation of 
intraday and inter day were calculated and presented in Table 20. The results revealed 
that the developed method was found to be reproducible in nature.  
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Table 20: Intra-day and inter-day precision of the developed method 
 
Drug 
 
Concentration 
(ng/spot) 
Intraday Interday 
Peak 
area* 
 
SD 
 
%RSD* 
Peak 
area* 
 
SD 
 
%RSD* 
 
TENE 
4000 5382.2 48.12 0.89 5392.5 51.89 0.96 
8000 9982.5 102.36 1.02 9986.3 105.05 1.05 
16000 17637.5 294.54 1.47 17983.6 256.80 1.63 
 
GLI 
200 4218.2 46.01 1.09 4209.3 60.77 1.44 
400 7128.5 83.58 1.17 7978.5 95.96 1.22 
800 12853.5 212.10 1.54 12448.4 169.16 1.63 
*mean of five observations 
 Acceptance criteria  
            The results complied with an acceptance criteria since the percentage relative 
standard deviation of  peak areas of  TENE and GLI were found to be with in the limit ie, 
NMT 2%. 
Table 21: Repeatability 
Conc. of TENE 
(ng/spot) 
Peak 
Area* 
 
% RSD* 
Conc. of GLI 
(ng/spot) 
Peak 
Area* 
 
% RSD* 
 
8000 
 
9987.6 
 
0.98 
 
 
400 
 
7198.4 
 
1.41 
* mean of five observations 
 
 
Acceptance criteria 
The results complied with an acceptance criteria since the percentage relative 
standard deviation was found to be within limit ie, NMT 2%. 
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4. LOD and LOQ: 
 
Table 22: LOD and LOQ 
Parameter TENE                                                             
(ng/spot) 
GLI                                           
(ng/spot) 
LOD 24.0 6.24 
LOQ 72.74 4.93 
* mean of five observations 
 
5. Ruggedness: 
 
Table 23: Ruggedness 
Drug Concentration    
(ng/spot) 
Mean Peak area* % R.S.D* 
Day I, Analyst I 
TENE 8000 9958.6 1.12 
GLI 400 7169.9 1.04 
Day II, Analyst II 
TENE 8000 9989.7 1.23 
GLI 400 7235.7 1.18 
*mean of five values.                                                       
The sample was analyzed by a different chemist and same instruments on a 
different day. The method is rugged because the percentage relative standard deviation 
was found to be with in the limit i.e., NMT 2%.  
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6. Robustness: 
The Robustness studies were performed for the standard solutions and presented 
in Table 24. This method was found to be robust because the percentage recovery were 
within the limit ie, ± 2%. 
Table 24: Robustness studies 
 
Parameter 
 
Modification 
Percentage Recovery (%) 
TENE GLI 
Mobile Phase Ratio 
1.5:2:1.5 98.43 99.56 
1:1.5:2.5 98.32 98.56 
Development 
Distance 
9 mm 98.56 98.92 
Detection 
Wavelength(nm) 
244 nm 98.96 98.82 
Slit Dimension 5.00 x .30m micro 98.65 98.76 
              
7. Analysis of formulation: 
 
Table 25: Assay Teneligliptin hydrobromide hydrate and Glimepiride in tablet 
dosage form  
 
 
 
Formulation 
Labelled amount 
(mg) 
Amount Found 
(mg) 
Percentage 
assay 
(%) 
%R.S.D* 
TENE GLI TENE GLI TENE  GLI TENE GLI 
20 1 19.98 0.99 99.28 99.64 1.02 1.17 
*mean of five observations 
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    Fig. 22: Chromatogram of standard (100 ng/spot of GLI and 2000 ng/spot TENE) 
 
 
   Fig. 23: Chromatogram of standard (200 ng/spot of GLI and 4000 ng/spot TENE) 
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   Fig. 24: Chromatogram of standard (400 ng/spot of GLI and 8000 ng/spot TENE) 
 
 
 
  Fig. 25: Chromatogram of standard (800 ng/spot of GLI and 16000 ng/spot TENE) 
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Fig. 26: Chromatogram of standard (1000ng/spotof GLI and 20000 ng/spot       
TENE) 
 
                       Fig. 27: Chromatogram of sample(8000 ng/spot of TENE and 400 
ng/spot GLI) 
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  Fig. 28: Over all 3D diagram for TENE and GLI (standard and sample) 
 
                                  Fig. 29: Overlay spectrum of Glimepiride 
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                                  Fig. 30: Overlay spectrum of Teneligliptin 
 
      Fig 31: Overlay spectrum of standard (TENE and GLI) 
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                 Fig. 32: Chromatogram of TENE and GLI (Standard and sample) 
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                                                  8. SUMMARY 
             The method was designed to validate RP-HPLC and HPTLC method for the 
determination of Teneligliptin hydrobromide hydrate and Glimepiride in bulk drug and 
formulations. The developed method was validated by using the following parameters 
like linearity, precision, accuracy, LOD, LOQ, system suitability, specificity, ruggedness 
and robustness. All the parameters were found to be satisfactory. 
 
HPLC METHOD: 
 A rapid, sensitive RP-HPLC method for the simultaneous determination 
of Teneligliptin hydrobromide hydrate and Glimepiride was developed 
and validated. 
 The method development was carried out by using a mobile phase 
consisting of 65:35 of Acetonitrile: Phosphate Buffer was selected at pH 
3.0 (which was adjusted with orthophosphoric acid). The detection was 
carried out by using PDA detector at 246nm. The column was 
phenomenex C18 (250 X 4.6mm, 5µ). The flow rate was selected as 
1ml/min. 
 The retention time of Teneligliptin hydrobromide hydrate and 
Glimepiride was found to be 5.8min and 9.41min respectively. 
 The linearity range of Teneligliptin hydrobromide hydrate 5-25 μg/ml and 
Glimepiride 0.25-1.25 μg/ml was found to be obeying linearity with the 
correlation coefficient of 0.99 respectively. 
 The proposed and validated method was successfully applied to determine 
Teneligliptin hydrobromide hydrate and Glimepiride in their combined 
dosage form. The results obtained for Teneligliptin hydrobromide hydrate 
and Glimepiride were comparable with the corresponding labeled 
amounts. 
 The tailing factor of is Teneligliptin hydrobromide hydrate and 
Glimepiride 0.98 and 1.02 and the number of theoretical plates were 
found to be 5069 and 5909 respectively, indicating the efficiency of 
column and these parameters represent the specificity of the method. 
 The recovery experiment was performed by the standard addition method. 
The percentage recovery of Teneligliptin hydrobromide hydrate and 
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Glimepiride was found to be 98.83 to 99.83% and 99.60 to 99.90% 
respectively. The results indicate that proposed method is highly accurate. 
 The RSD values of Teneligliptin hydrobromide hydrate and Glimepiride 
interday (0.35-0.36% and 0.23-0.25%) and intraday (0.39% and 0.25%), 
reveal that the proposed method is precise. 
 LOD and LOQ values for Teneligliptin hydrobromide hydrate (1.32 μg/ml 
and 3.56 μg/ml) and (0.90 μg/ml and 2.73 μg/ml) showed that the method 
is sensitive for the determination of Teneligliptin hydrobromide hydrate 
and Glimepiride. 
 There is no other co eluting peak with the main peaks, hence the RP-
HPLC method is specific for the estimation of Teneligliptin hydrobromide 
hydrate and Glimepiride.  
 The validated method was found to be robust. 
 The ruggedness of the method demonstrated that different operational and 
environmental variables had only a minimal influence on the test results. 
HPTLC METHOD: 
 A HPTLC method has been developed and validated for the simultaneous 
estimation of Teneligliptin hydrobromide hydrate and Glimepiride in pure 
and pharmaceutical dosage form. 
 Good separation of analytes were achieved by using Toluene: Methanol: 
Triethylamine (1:3:1 v/v/v) as a mobile phase on precoated silica gel 60F 
254 plates. 
 The Rf values for Glimepiride and Teneligliptin hydrobromide hydrate 
were found to be 0.48 and 0.60 respectively. The linearity range of 
Glimepiride (100 – 1000 ng/spot) and Teneligliptin hydrobromide hydrate 
(2000 – 20000 ng/spot) was found obey linearity with a correlation 
coefficient of 0.9935 and 0.9968 respectively. 
 The proposed validated method was successfully applied to determine 
Teneligliptin hydrobromide hydrate and Glimepiride in combined dosage 
form. The results obtained for Teneligliptin hydrobromide hydrate and 
Glimepiride was comparable with the corresponding labeled amounts. 
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 The percentage recovery of Teneligliptin hydrobromide hydrate and 
Glimepiride was found to be 99.56 to 99.87% and 99.64 to 99.92%, which 
indicate that proposed method is highly accurate. 
 The RSD values of Teneligliptin hydrobromide hydrate and Glimepiride 
for interday (0.96-1.63% and 1.22-1.63%) and intraday (0.89-1.47% and 
1.09-1.54%), reveal that the proposed method is precise. 
 LOD and LOQ for Teneligliptin hydrobromide hydrate was 24.0 and 
72.74 (ng/spot) and for Glimepiride was 6.24 and 4.93 ng/spot 
respectively. 
 There is no other co eluting peak with the main peaks, hence the HPTLC 
method is specific for the estimation of Teneligliptin hydrobromide 
hydrate and Glimepiride. 
 The validated method was found to be robust. The ruggedness of the 
method demonstrated that different operational and environmental 
variables had only a minimal influence on the test results. 
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                                                      9. CONCLUSION 
 The novel RP-HPLC and HPTLC methods were validated by determining system 
suitability, specificity, precision, linearity, accuracy, stability, LOD, LOQ, 
ruggedness and robustness parameters and found to be satisfactory both in RP-
HPLC and HPTLC method. 
 The standard preparations were done in the range of 5-25 μg/ml for TENE and 
0.25-1.25 μg/ml for GLI. The assay concentration were linear (correlation 
coefficient, R²=0.9983 and 0.9967, n=5) in the developed RP-HPLC method. 
 There was no other co eluting peak with TENE and GLI peaks and hence both 
RP-HPLC and HPTLC methods are specific for the estimation of both TENE and 
GLI in the presence of other excipients. 
 In HPLC, the flow rate is reduced (1ml/min) as compared with previously 
reported methods in literatures. 
 The developed method is eco-friendly as the mobile phase used is biodegradable. 
 It is also economic since the solvent used is of lower cost when compared with 
the other literatures already reported. 
 In HPTLC a newer method has been developed. 
 The standard preparations in the range of 2000 (ng/spot) to 20000 (ng/spot) for 
TENE and 100 (ng/spot) to 1000 (ng/spot) for GLI. The assay standard 
concentration were linear for both TENE and GLI (correlation coefficient, 
R²=0.9966 and 0.9938, n=5) in developed HPTLC method. 
 The ruggedness of both the RP-HPLC and HPTLC method demonstrated that 
different operational and environmental variables had very little influence with in 
the limit on the test results. 
 The method was completely validated showing satisfactory data for all the 
method validation parameters that were tested.   
 It was concluded that, the developed method offered several advantages such as, 
rapid, cost effective, simple mobile phase, comparative short run time made it 
specific and reliable and it is in good agreement with the label claim of the drug. 
The additives present in the pharmaceutical formulation of the assayed sample 
did not interfere with determination of TENE and GLI. 
 Both RP-HPLC and HPTLC methods can be used for routine analysis of TENE 
and GLI in their combined dosage form without any interference of excipients. 
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                                            11. ABSTRACT 
       
        A novel RP-HPLC and HPTLC method were developed and validated for the 
simultaneous estimation of Teneligliptin hydrobromide hydrate and Glimepiride.RP- 
HPLC method was developed in reverse phase mode using acetonitrile and phosphate 
buffer (pH 3 adjusted with orthophosphoric acid) as mobile phase in the ratio of 65:35 
(v/v) at a flow rate 1ml/min and. Quantitation was achieved with ultraviolet detection at 
246nm and retention time was found to be 5.8 min and 9.41 min for Teneligliptin 
hydrobromide hydrate and Glimepiride respectively. The linearity was found to be in the 
range of 5 – 25 ng/ml and 0.25 – 1.25 ng/ml and recovery were found to be 98.80 and 
99.68 % for Teneligliptin hydrobromide hydrate and Glimepiride respectively. The 
developed method is co-friendly and the peaks were more resolved when compared to 
the previous literatures with reduced flow rate.  HPTLC method wasdeveloped on Merck 
TLC aluminium sheets of silica gel 60 F₂₂₂ using Toluene: Methanol: Triethylamine 
(1: 3: 1 v/v/v) as mobile phase. Quantitation was achieved with ultraviolet detection a 
246 nm and Rf value was found to be 0.48 and 0.60 for Glimepiride and Teneligliptin 
hydrobromide hydrate respectively. The linearity was found to be in the range of 2000 – 
20000 ng/spot and 100 – 1000 ng/spot and mean recovery was found to be 99.64 and 
99.28 % of Glimepiride and Teneligliptin hydrobromide hydrate respectively. Both 
HPLC and HPTLC were found to be specific since there was no co-eluting peak with 
drug 
